Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti-Tat	B-protein
single-chain	I-protein
intrabodies	I-protein
and	O
NF-kappa	O
B	O
antagonists	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
,	O
an	O
early	O
regulatory	B-protein
protein	I-protein
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	B-DNA
response	I-DNA
element	I-DNA
(	O
TAR	B-DNA
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Tat	O
also	O
superactivates	O
the	O
HIV-1	B-DNA
promoter	I-DNA
through	O
a	O
TAR	B-DNA
-independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha-induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	B-protein
)	O
-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
inhibitors	O
of	O
Tat	B-protein
and	O
NF-kappa	B-protein
B	I-protein
cooperatively	O
down-regulate	O
this	O
Tat	B-protein
-mediated	O
LTR	B-DNA
superactivation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti-Tat	B-protein
single-chain	I-protein
intracellular	I-protein
antibody	I-protein
(	O
sFv	B-protein
intrabody	I-protein
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	B-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go-6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	B-DNA
LTR	I-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti-Tat	B-protein
sFv	I-protein
intrabodies	I-protein
and	O
the	O
two	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV-1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
alone	O
or	O
the	O
anti-	O
Tat	B-protein
sFv	I-protein
intrabodies	I-protein
alone	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	B-cell_line
cells	I-cell_line
and	O
prolong	O
clinical	O
benefit	O
.	O

JOURNAL	NULL
OF	NULL
VirRoLOGY	NULL
,	NULL
Sept.	NULL
1997	NULL
,	NULL
p.	NULL
6486-6494	NULL
0022-538X	NULL
,	NULL
/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Inhibition	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Replication	NULL
In	NULL
Vitro	NULL
by	NULL
a	NULL
Novel	NULL
Combination	NULL
of	NULL
Anti-Tat	NULL
Single-Chain	NULL
Intrabodies	NULL
and	NULL
NF-KB	NULL
Antagonists	NULL
ABNER	NULL
M.	NULL
MHASHILKAR	NULL
,	NULL
'	NULL
DEBAJIT	NULL
K.	NULL
BISWAS	NULL
,	NULL
JOYCE	NULL
ARTHUR	NULL
B.	NULL
PARDEE	NULL
,	NULL
``	NULL
AND	NULL
WAYNE	NULL
A	NULL
.	NULL

MARASCO	NULL
!	NULL

***	NULL
Division	NULL
of	NULL
Human	NULL
Retrovirology	NULL
}	NULL
and	NULL
Departments	NULL
of	NULL
Cell	NULL
Growth	NULL
and	NULL
Regulation	NULL
``	NULL
and	NULL
Medicine	NULL
,	NULL
``	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
.	NULL

Received	NULL
14	NULL
October	NULL
1996/Accepted	NULL
30	NULL
May	NULL
1997	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
Tat	NULL
,	NULL
an	NULL
early	NULL
regulatory	NULL
protein	NULL
that	NULL
is	NULL
critical	NULL
for	NULL
viral	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
,	NULL
transactivates	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
via	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
transactivation	NULL
response	NULL
element	NULL
(	NULL
TAR	NULL
)	NULL
and	NULL
,	NULL
along	NULL
with	NULL
other	NULL
cellular	NULL
factors	NULL
,	NULL
increases	NULL
viral	NULL
transcription	NULL
initiation	NULL
and	NULL
elongation	NULL
.	NULL

Tat	NULL
also	NULL
superactivates	NULL
the	NULL
HIV-1	NULL
promoter	NULL
through	NULL
a	NULL
TAR-independent	NULL
mechanism	NULL
,	NULL
including	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha-induced	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
-dependent	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
and	NULL
inhibitors	NULL
of	NULL
Tat	NULL
and	NULL
NF-B	NULL
cooperatively	NULL
down-regulate	NULL
this	NULL
Tat-mediated	NULL
LTR	NULL
superactivation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
a	NULL
combined	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
strategy	NULL
using	NULL
two	NULL
PKC	NULL
(	NULL
NF-B	NULL
)	NULL
inhibitors	NULL
,	NULL
pentoxifylline	NULL
(	NULL
PTX	NULL
)	NULL
and	NULL
and	NULL
a	NULL
stably	NULL
expressed	NULL
anti-Tat	NULL
single-chain	NULL
intracellular	NULL
antibody	NULL
(	NULL
sFv	NULL
intrabody	NULL
)	NULL
was	NULL
employed	NULL
to	NULL
obtain	NULL
cooperative	NULL
inhibition	NULL
of	NULL
both	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
PTX	NULL
and	NULL
Go-6976	NULL
resulted	NULL
in	NULL
cooperative	NULL
inhibition	NULL
of	NULL
both	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
combined	NULL
use	NULL
of	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
and	NULL
the	NULL
two	NULL
NF-KB	NULL
inhibitors	NULL
retained	NULL
the	NULL
virus	NULL
in	NULL
the	NULL
latent	NULL
state	NULL
for	NULL
as	NULL
long	NULL
as	NULL
45	NULL
days	NULL
.	NULL

The	NULL
combined	NULL
treatment	NULL
resulted	NULL
in	NULL
more	NULL
durable	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
than	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
NF-KB	NULL
inhibitors	NULL
alone	NULL
or	NULL
the	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
alone	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
future	NULL
clinical	NULL
gene	NULL
therapy	NULL
trials	NULL
,	NULL
a	NULL
combined	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
strategy	NULL
like	NULL
the	NULL
one	NULL
reported	NULL
here	NULL
may	NULL
improve	NULL
the	NULL
survival	NULL
of	NULL
transduced	NULL
cells	NULL
and	NULL
prolong	NULL
clinical	NULL
benefit	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
is	NULL
the	NULL
primary	NULL
etiologic	NULL
agent	NULL
of	NULL
AIDS	NULL
,	NULL
a	NULL
fatal	NULL
disease	NULL
that	NULL
results	NULL
from	NULL
the	NULL
gradual	NULL
destruction	NULL
of	NULL
the	NULL
helper	NULL
T-cell	NULL
population	NULL
in	NULL
infected	NULL
individuals	NULL
(	NULL
21	NULL
,	NULL
23	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Tat	NULL
is	NULL
a	NULL
regulatory	NULL
protein	NULL
encoded	NULL
by	NULL
the	NULL
HIV-1	NULL
genome	NULL
that	NULL
plays	NULL
a	NULL
unique	NULL
role	NULL
in	NULL
the	NULL
emergence	NULL
of	NULL
the	NULL
virus	NULL
from	NULL
the	NULL
latent	NULL
state	NULL
.	NULL

Tat	NULL
is	NULL
known	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
of	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
33	NULL
,	NULL
38	NULL
,	NULL
42	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
in	NULL
the	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
all	NULL
HIV	NULL
RNAs	NULL
called	NULL
the	NULL
transactivation	NULL
response	NULL
element	NULL
(	NULL
TAR	NULL
)	NULL
(	NULL
nucleotides	NULL
+1	NULL
to	NULL
+44	NULL
)	NULL
is	NULL
required	NULL
for	NULL
Tat-mediated	NULL
transactivation	NULL
(	NULL
3	NULL
,	NULL
19	NULL
,	NULL
51	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Tat	NULL
binds	NULL
with	NULL
high	NULL
efficiency	NULL
to	NULL
a	NULL
bulge	NULL
region	NULL
in	NULL
a	NULL
stable	NULL
stem-loop	NULL
structure	NULL
of	NULL
the	NULL
TAR	NULL
RNA	NULL
and	NULL
then	NULL
interacts	NULL
with	NULL
a	NULL
transcription	NULL
initiation	NULL
complex	NULL
(	NULL
26	NULL
,	NULL
37	NULL
)	NULL
composed	NULL
of	NULL
Tat	NULL
and	NULL
DNA-	NULL
and	NULL
RNA-binding	NULL
proteins	NULL
(	NULL
24	NULL
,	NULL
25	NULL
,	NULL
31	NULL
,	NULL
32	NULL
,	NULL
42	NULL
,	NULL
48	NULL
,	NULL
52	NULL
,	NULL
56	NULL
,	NULL
57	NULL
)	NULL
to	NULL
primarily	NULL
stimulate	NULL
transcription	NULL
initiation	NULL
and	NULL
to	NULL
increase	NULL
transcription	NULL
elongation	NULL
(	NULL
33	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Tat	NULL
has	NULL
other	NULL
modes	NULL
of	NULL
action	NULL
as	NULL
well	NULL
.	NULL

Expression	NULL
of	NULL
Tat	NULL
in	NULL
human	NULL
cells	NULL
in	NULL
culture	NULL
leads	NULL
to	NULL
transactivation	NULL
and	NULL
overexpres-sion	NULL
of	NULL
cellular	NULL
genes	NULL
encoding	NULL
cytokines	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
TNF-B	NULL
,	NULL
and	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
48a	NULL
,	NULL
54	NULL
,	NULL
59	NULL
)	NULL
,	NULL
some	NULL
of	NULL
which	NULL
in	NULL
turn	NULL
can	NULL
activate	NULL
viral	NULL
transcription	NULL
through	NULL
their	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NF-kB	NULL
by	NULL
TNF-a	NULL
occurs	NULL
through	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
-mediated	NULL
pathway	NULL
(	NULL
6	NULL
)	NULL
.	NULL

NF-kB	NULL
binding	NULL
to	NULL
enhancer	NULL
el-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Human	NULL
Ret-rovirology	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
44	NULL
Binney	NULL
St.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
632-2153	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
632-3889	NULL
.	NULL

E-mail	NULL
:	NULL
wayne_marasco	NULL
@	NULL
dfci.harvard.edu	NULL
.	NULL

6486	NULL
ements	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
can	NULL
lead	NULL
to	NULL
TAR-independent	NULL
(	NULL
NF-kB	NULL
dependent	NULL
)	NULL
activation	NULL
of	NULL
viral	NULL
transcription	NULL
by	NULL
Tat	NULL
(	NULL
7	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Superactivation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
is	NULL
thus	NULL
induced	NULL
by	NULL
the	NULL
concerted	NULL
interaction	NULL
of	NULL
the	NULL
cellular	NULL
transactivator	NULL
NF-kB	NULL
and	NULL
Tat	NULL
(	NULL
1	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
31	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
due	NULL
to	NULL
its	NULL
multifunctional	NULL
roles	NULL
in	NULL
viral	NULL
and	NULL
cytokine	NULL
gene	NULL
transactivation	NULL
,	NULL
Tat	NULL
represents	NULL
an	NULL
important	NULL
target	NULL
for	NULL
HIV	NULL
therapy	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Intracellular	NULL
immunization	NULL
is	NULL
a	NULL
form	NULL
of	NULL
gene	NULL
therapy	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
HIV-1	NULL
infection	NULL
and	NULL
AIDS	NULL
that	NULL
is	NULL
aimed	NULL
at	NULL
the	NULL
stable	NULL
introduction	NULL
into	NULL
susceptible	NULL
cells	NULL
of	NULL
genetic	NULL
elements	NULL
that	NULL
inhibit	NULL
viral	NULL
replication	NULL
,	NULL
so	NULL
called	NULL
resistance	NULL
genes	NULL
(	NULL
2	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Intracellular	NULL
antibodies	NULL
,	NULL
or	NULL
intrabodies	NULL
,	NULL
are	NULL
a	NULL
recent	NULL
addition	NULL
to	NULL
the	NULL
field	NULL
of	NULL
intracellular	NULL
immunization-based	NULL
strategies	NULL
that	NULL
are	NULL
being	NULL
used	NULL
to	NULL
treat	NULL
HIV-1	NULL
infection	NULL
(	NULL
11-13	NULL
,	NULL
20	NULL
,	NULL
34	NULL
,	NULL
36	NULL
,	NULL
39	NULL
,	NULL
40	NULL
,	NULL
41	NULL
,	NULL
44	NULL
,	NULL
45	NULL
,	NULL
49	NULL
,	NULL
55	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
anti-Tat	NULL
single-chain	NULL
(	NULL
sFv	NULL
)	NULL
intrabodies	NULL
have	NULL
been	NULL
examined	NULL
in	NULL
stably	NULL
transfected	NULL
CD4	NULL
*	NULL
T	NULL
lymphocytes	NULL
(	NULL
44	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
demonstrated	NULL
that	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
effectively	NULL
sequestered	NULL
Tat	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
blocked	NULL
its	NULL
transport	NULL
to	NULL
the	NULL
nucleus	NULL
of	NULL
the	NULL
cell	NULL
,	NULL
and	NULL
inhibited	NULL
the	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
both	NULL
stably	NULL
transfected	NULL
cells	NULL
(	NULL
44	NULL
)	NULL
and	NULL
transduced	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
from	NULL
HIV-1-infected	NULL
individuals	NULL
(	NULL
49	NULL
)	NULL
,	NULL
marked	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
was	NULL
observed	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
also	NULL
demonstrated	NULL
that	NULL
superactivation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
cooperative	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Tat	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
pentoxifylline	NULL
(	NULL
PTX	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
PKC	NULL
,	NULL
PKA	NULL
,	NULL
and	NULL
NF-kB	NULL
(	NULL
4	NULL
,	NULL
6	NULL
,	NULL
16	NULL
,	NULL
17	NULL
)	NULL
,	NULL
plus	NULL
Ro24-7429	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
Tat	NULL
(	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
cooperative	NULL
effect	NULL
of	NULL
these	NULL
two	NULL
inhibitors	NULL
on	NULL
HIV-1	NULL
replication	NULL
was	NULL
not	NULL
examined	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
present	NULL
study	NULL
was	NULL
undertaken	NULL
to	NULL
examine	NULL
whether	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
combined	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
therapeutic	NULL
strategies	NULL
that	NULL
are	NULL
targeted	NULL
to	NULL
Tat	NULL
and	NULL
are	NULL
aimed	NULL
at	NULL
inhibiting	NULL
both	NULL
the	NULL
TAR-dependent	NULL
and	NULL
NF-	NULL
«	NULL
xB-dependent	NULL
Tat	NULL
activation	NULL
pathways	NULL
simultaneously	NULL
would	NULL
result	NULL
in	NULL
a	NULL
more	NULL
potent	NULL
inhibition	NULL
of	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
than	NULL
would	NULL
any	NULL
single	NULL
agent	NULL
or	NULL
strategy	NULL
alone	NULL
.	NULL

Because	NULL
activation	NULL
of	NULL
NF-KB	NULL
is	NULL
known	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
PKC	NULL
,	NULL
we	NULL
tested	NULL
two	NULL
PKC	NULL
inhibitors	NULL
,	NULL
PTX	NULL
and	NULL
G6-6976	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
PKC	NULL
that	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
have	NULL
anti-HIV-1	NULL
activity	NULL
(	NULL
48	NULL
)	NULL
,	NULL
and	NULL
evaluated	NULL
their	NULL
effects	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
on	NULL
NF-KB	NULL
activation	NULL
and	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
PTX	NULL
and	NULL
G6-6976	NULL
on	NULL
HIV-1	NULL
replication	NULL
were	NULL
also	NULL
examined	NULL
in	NULL
cells	NULL
stably	NULL
expressing	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PTX	NULL
and	NULL
G6-6976	NULL
results	NULL
in	NULL
cooperative	NULL
inhibition	NULL
of	NULL
both	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
combined	NULL
use	NULL
of	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
and	NULL
the	NULL
two	NULL
NF-KB	NULL
inhibitors	NULL
resulted	NULL
in	NULL
more	NULL
durable	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
than	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
NF-kB	NULL
inhibitors	NULL
alone	NULL
or	NULL
the	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
alone	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

The	NULL
human	NULL
CD4*	NULL
T-lymphocyte	NULL
cell	NULL
lines	NULL
SupT1	NULL
(	NULL
SupT	NULL
)	NULL
and	NULL
Jurkat	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibeo/BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

with	NULL
glutamine	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
at	NULL
37°C	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
and	NULL
95	NULL
%	NULL
air	NULL
.	NULL

SupT	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
pRe/	NULL
CMV	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
(	NULL
SupT-vector	NULL
cells	NULL
)	NULL
or	NULL
constitutively	NULL
expressing	NULL
the	NULL
anti-HIV-1	NULL
Tat	NULL
sFv	NULL
intrabody	NULL
termed	NULL
sFvtat1Ck	NULL
(	NULL
SupT-sFvtat1Ck	NULL
cells	NULL
)	NULL
were	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
and	NULL
were	NULL
propagated	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
G418	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Company	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

at	NULL
500	NULL
pg/ml	NULL
.	NULL

PBMCs	NULL
were	NULL
isolated	NULL
from	NULL
leukopacks	NULL
(	NULL
obtained	NULL
from	NULL
the	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
Blood	NULL
Bank	NULL
)	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

The	NULL
CD4*	NULL
mononuclear	NULL
cells	NULL
were	NULL
selected	NULL
from	NULL
the	NULL
total	NULL
PBMC	NULL
population	NULL
with	NULL
anti-CD4-coated	NULL
cell	NULL
culture	NULL
flasks	NULL
(	NULL
GenCell	NULL
,	NULL
Santa	NULL
Clara	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

A	NULL
total	NULL
of	NULL
20	NULL
10°	NULL
PBMCs	NULL
were	NULL
resuspended	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
Ca**-	NULL
and	NULL
Mg**-free	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS/CMF	NULL
)	NULL
-1	NULL
mM	NULL
EDTA-0.5	NULL
%	NULL
human	NULL
gamma	NULL
globulins	NULL
(	NULL
Sig-ma	NULL
)	NULL
and	NULL
incubated	NULL
on	NULL
the	NULL
flask	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
flask	NULL
was	NULL
washed	NULL
five	NULL
times	NULL
with	NULL
PBS/CMF-1	NULL
mM	NULL
EDTA	NULL
.	NULL

After	NULL
the	NULL
final	NULL
wash	NULL
,	NULL
10	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
phytohemag-glutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
flask	NULL
,	NULL
which	NULL
was	NULL
then	NULL
incubated	NULL
for	NULL
circa	NULL
60	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

Reagents	NULL
and	NULL
plasmids	NULL
.	NULL

PTX	NULL
[	NULL
1-	NULL
(	NULL
5'-oxohexy1	NULL
)	NULL
-3,7-dimethyl	NULL
xanthine	NULL
]	NULL
and	NULL
Go6976	NULL
(	NULL
a	NULL
synthetic	NULL
nonglycosidic	NULL
indolocarbazole	NULL
)	NULL
were	NULL
gifts	NULL
from	NULL
Hoechst-Rous-sel	NULL
Pharmaceutical	NULL
,	NULL
Somerville	NULL
,	NULL
N.J.	NULL
,	NULL
and	NULL
Parke-Davis	NULL
Company	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Mich.	NULL
,	NULL
respectively	NULL
.	NULL

DEAE-dextran	NULL
,	NULL
geneticin	NULL
(	NULL
G418	NULL
)	NULL
,	NULL
and	NULL
PHA	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

Acetyl	NULL
coenzyme	NULL
A	NULL
was	NULL
purchased	NULL
from	NULL
Bochringer	NULL
Mannheim	NULL
,	NULL
and	NULL
TNF-a	NULL
was	NULL
obtained	NULL
from	NULL
Endogen	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL

pHIV-1	NULL
LTR-CAT	NULL
was	NULL
obtained	NULL
from	NULL
G.	NULL
Nabel	NULL
,	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
Ann	NULL
Arbor	NULL
;	NULL
expression	NULL
plasmid	NULL
pSVTat	NULL
was	NULL
obtained	NULL
from	NULL
J.	NULL
Sodroski	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL

Transfection	NULL
experiments	NULL
.	NULL

Transient	NULL
transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
7	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
5	NULL
pg	NULL
of	NULL
plasmid	NULL
pHIV-1	NULL
LTR-CAT	NULL
alone	NULL
or	NULL
,	NULL
for	NULL
cotransfection	NULL
experiments	NULL
,	NULL
2	NULL
pg	NULL
each	NULL
of	NULL
plasmids	NULL
pHIV-1	NULL
LTR-CAT	NULL
and	NULL
pSVTat	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
media	NULL
without	NULL
or	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
PTX	NULL
(	NULL
10	NULL
to	NULL
300	NULL
M	NULL
)	NULL
or	NULL
G6-6976	NULL
(	NULL
10	NULL
to	NULL
300	NULL
nM	NULL
)	NULL
and	NULL
were	NULL
used	NULL
either	NULL
singly	NULL
or	NULL
in	NULL
combination	NULL
.	NULL

Approximately	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
with	NULL
pHIV-1	NULL
LTR-CAT	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNF-a	NULL
or	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
;	NULL
18	NULL
h	NULL
later	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
activity	NULL
in	NULL
cell	NULL
extracts	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

In	NULL
the	NULL
pSVTat/pHIV-1	NULL
LTR-CAT	NULL
cotransfection	NULL
experiments	NULL
,	NULL
CAT	NULL
assays	NULL
were	NULL
performed	NULL
60	NULL
h	NULL
posttransfection	NULL
.	NULL

In	NULL
all	NULL
of	NULL
the	NULL
transfection	NULL
studies	NULL
,	NULL
control	NULL
plasmid	NULL
pSV-lecZ	NULL
was	NULL
routinely	NULL
cotransfected	NULL
with	NULL
the	NULL
specific	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
to	NULL
normalize	NULL
the	NULL
transfection	NULL
efficiency	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
B-galactosidase	NULL
activity	NULL
in	NULL
control	NULL
and	NULL
drug-treated	NULL
cells	NULL
were	NULL
the	NULL
same	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
drugs	NULL
did	NULL
not	NULL
influence	NULL
another	NULL
viral	NULL
promoter	NULL
that	NULL
lacks	NULL
the	NULL
classic	NULL
NF-	NULL
«	NULL
B	NULL
motif	NULL
and	NULL
were	NULL
not	NULL
toxic	NULL
to	NULL
the	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
separate	NULL
experiments	NULL
demonstrated	NULL
that	NULL
G6-6976	NULL
,	NULL
like	NULL
PTX	NULL
(	NULL
5	NULL
)	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
NF-	NULL
«	NULL
B-lacking	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter-driven	NULL
reporter	NULL
CAT	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1E	NULL
)	NULL
.	NULL

EMSA	NULL
.	NULL

The	NULL
level	NULL
of	NULL
active	NULL
NF-B	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
of	NULL
control	NULL
and	NULL
treated	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
electophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

A	NULL
``	NULL
P-labeled	NULL
double-stranded	NULL
oligonucleotide	NULL
probe	NULL
encoding	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
motifs	NULL
was	NULL
used	NULL
for	NULL
EMSA	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

HIV-1	NULL
challenge	NULL
experiments	NULL
.	NULL

Stably	NULL
transfected	NULL
SupT-vector	NULL
and	NULL
SupT-sFvtat1Ck	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
overnight	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
PTX	NULL
(	NULL
300	NULL
wM	NULL
,	NULL
final	NULL
concentration	NULL
)	NULL
and/or	NULL
G6-6976	NULL
(	NULL
300	NULL
nM	NULL
,	NULL
final	NULL
concentra-	NULL
ANTI-HIV-1	NULL
PHARMACOLOGIC-GENETIC	NULL
STRATEGY	NULL
-	NULL
6487	NULL
tion	NULL
)	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
either	NULL
the	NULL
laboratory	NULL
HIV-1	NULL
strain	NULL
II-B	NULL
or	NULL
a	NULL
syncytium-inducing	NULL
(	NULL
ST	NULL
)	NULL
European	NULL
primary	NULL
HIV-1	NULL
isolate	NULL
(	NULL
obtained	NULL
from	NULL
Jan	NULL
Albert	NULL
,	NULL
Karolinska	NULL
Institute	NULL
,	NULL
Stockholm	NULL
,	NULL
Sweden	NULL
)	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
(	NULL
MOT	NULL
)	NULL
of	NULL
0.5	NULL
.	NULL

Six	NULL
hours	NULL
after	NULL
challenge	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
thoroughly	NULL
washed	NULL
and	NULL
fresh	NULL
medium	NULL
(	NULL
without	NULL
or	NULL
with	NULL
appropriate	NULL
drugs	NULL
)	NULL
was	NULL
added	NULL
.	NULL

Supernatants	NULL
were	NULL
then	NULL
harvested	NULL
on	NULL
alternate	NULL
days	NULL
with	NULL
resuspension	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
corresponding	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
without	NULL
or	NULL
with	NULL
appropriate	NULL
drugs	NULL
)	NULL
.	NULL

Viral	NULL
particles	NULL
in	NULL
collected	NULL
supernatants	NULL
were	NULL
analyzed	NULL
by	NULL
using	NULL
a	NULL
radioimmunoassay	NULL
kit	NULL
for	NULL
HIV-1	NULL
p24	NULL
protein	NULL
(	NULL
DuPont	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
44	NULL
)	NULL
.	NULL

PBMCs	NULL
were	NULL
activated	NULL
with	NULL
either	NULL
PHA	NULL
(	NULL
4	NULL
pg/ml	NULL
;	NULL
Sigma	NULL
)	NULL
or	NULL
OKT3	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
cultured	NULL
continuously	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
plus	NULL
IL-2	NULL
(	NULL
20	NULL
U/m1	NULL
)	NULL
without	NULL
or	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
.	NULL

After	NULL
3	NULL
days	NULL
of	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
challenged	NULL
with	NULL
either	NULL
of	NULL
two	NULL
SI	NULL
European	NULL
primary	NULL
HIV-1	NULL
isolates	NULL
.	NULL

Supernatants	NULL
were	NULL
collected	NULL
every	NULL
third	NULL
day	NULL
and	NULL
assayed	NULL
for	NULL
p24	NULL
antigen	NULL
.	NULL

Transduction	NULL
of	NULL
PBMCs	NULL
and	NULL
CD4*	NULL
mononuclear	NULL
cells	NULL
and	NULL
HIV-1	NULL
challenge	NULL
.	NULL

The	NULL
sFviat1Ck	NULL
intrabody	NULL
gene	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
shuttle	NULL
vector	NULL
LNCX	NULL
MuLV	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
immediate-early	NULL
promoter	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
empty	NULL
LNCX	NULL
(	NULL
LN	NULL
)	NULL
or	NULL
LN-sFvtat1Ck	NULL
vector	NULL
was	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
into	NULL
the	NULL
ecotropic	NULL
cell	NULL
line	NULL
$	NULL
CRE	NULL
(	NULL
46	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
the	NULL
supernatants	NULL
from	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
cleared	NULL
by	NULL
low-speed	NULL
centrifugation	NULL
(	NULL
3,000	NULL
%	NULL
g	NULL
)	NULL
,	NULL
and	NULL
used	NULL
to	NULL
infect	NULL
the	NULL
amphotrophic	NULL
packaging	NULL
cell	NULL
line	NULL
PG13	NULL
.	NULL

Producer	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
using	NULL
G418	NULL
and	NULL
hypoxanthine-aminopterin-thymidine	NULL
selection	NULL
.	NULL

Following	NULL
establishment	NULL
of	NULL
stable	NULL
PG13	NULL
sub-clones	NULL
by	NULL
limiting	NULL
dilution	NULL
,	NULL
retrovirus-containing	NULL
supernatants	NULL
were	NULL
harvested	NULL
,	NULL
filtered	NULL
,	NULL
and	NULL
used	NULL
to	NULL
transduce	NULL
PBMCs	NULL
.	NULL

Transduction	NULL
was	NULL
performed	NULL
on	NULL
3	NULL
consecutive	NULL
days	NULL
with	NULL
an	NULL
initial	NULL
6	NULL
h	NULL
of	NULL
phosphate	NULL
starvation	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
1-h	NULL
centrifugation	NULL
of	NULL
the	NULL
cells	NULL
and	NULL
retroviral	NULL
supernatants	NULL
(	NULL
1,000	NULL
x	NULL
g	NULL
,	NULL
32°C	NULL
)	NULL
and	NULL
overnight	NULL
incubation	NULL
at	NULL
32°C	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
fresh	NULL
medium	NULL
,	NULL
resuspended	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
U/ml	NULL
)	NULL
and	NULL
G418	NULL
(	NULL
800	NULL
pg/tl	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
changed	NULL
on	NULL
day	NULL
5	NULL
.	NULL

After	NULL
10	NULL
days	NULL
in	NULL
culture	NULL
,	NULL
the	NULL
cell	NULL
were	NULL
washed	NULL
and	NULL
stimulated	NULL
with	NULL
irradiated	NULL
human	NULL
PBMCs	NULL
(	NULL
5,000	NULL
rads	NULL
)	NULL
at	NULL
a	NULL
ratio	NULL
of	NULL
1:10	NULL
(	NULL
transduced	NULL
cells/feeders	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
.	NULL

Four	NULL
days	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fed	NULL
with	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
U/ml	NULL
!	NULL
)	NULL

and	NULL
G418	NULL
(	NULL
800	NULL
pg/ml	NULL
)	NULL
.	NULL

When	NULL
cells	NULL
started	NULL
to	NULL
expand	NULL
(	NULL
circa	NULL
days	NULL
10	NULL
to	NULL
14	NULL
)	NULL
,	NULL
they	NULL
were	NULL
washed	NULL
,	NULL
equilibrated	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
PTX	NULL
(	NULL
300	NULL
uM	NULL
)	NULL
plus	NULL
G6-6976	NULL
(	NULL
300	NULL
nM	NULL
)	NULL
,	NULL
and	NULL
then	NULL
challenged	NULL
with	NULL
either	NULL
of	NULL
two	NULL
SI	NULL
European	NULL
primary	NULL
HIV-1	NULL
isolates	NULL
of	NULL
HIV-1	NULL
.	NULL

Viral	NULL
replication	NULL
was	NULL
monitored	NULL
by	NULL
the	NULL
p24	NULL
antigen	NULL
capture	NULL
assay	NULL
as	NULL
described	NULL
earlier	NULL
.	NULL

Transduction	NULL
efficiency	NULL
of	NULL
the	NULL
PBMCs	NULL
was	NULL
determined	NULL
by	NULL
PCR	NULL
amplification	NULL
with	NULL
appropriate	NULL
primers	NULL
of	NULL
the	NULL
neomycin	NULL
gene	NULL
as	NULL
described	NULL
by	NULL
Morgan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
47	NULL
)	NULL
.	NULL

Twenty-four	NULL
hours	NULL
after	NULL
the	NULL
last	NULL
transduction	NULL
,	NULL
20,000	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
PCR	NULL
band	NULL
intensity	NULL
was	NULL
compared	NULL
to	NULL
the	NULL
intensity	NULL
of	NULL
a	NULL
quantitation	NULL
curve	NULL
.	NULL

The	NULL
transduction	NULL
efficiency	NULL
was	NULL
estimated	NULL
to	NULL
be	NULL
around	NULL
10	NULL
to	NULL
15	NULL
%	NULL
.	NULL

RESULTS	NULL
Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
PMA	NULL
and	NULL
Tat	NULL
.	NULL

Basal	NULL
reporter	NULL
CAT	NULL
activity	NULL
,	NULL
using	NULL
our	NULL
standard	NULL
assay	NULL
conditions	NULL
and	NULL
the	NULL
wild-type	NULL
,	NULL
unmutated	NULL
plasmid	NULL
pHIV-1	NULL
LTR-CAT	NULL
,	NULL
was	NULL
stimulated	NULL
23-fold	NULL
by	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

A	NULL
markedly	NULL
greater	NULL
induction	NULL
of	NULL
CAT	NULL
was	NULL
observed	NULL
with	NULL
Tat	NULL
(	NULL
259-fold	NULL
)	NULL
compared	NULL
to	NULL
the	NULL
unstimulated	NULL
wild-type	NULL
HIV	NULL
promoter	NULL
construct	NULL
(	NULL
1.5-fold	NULL
)	NULL
.	NULL

Tat	NULL
induced	NULL
an	NULL
18-fold	NULL
up-regulation	NULL
of	NULL
the	NULL
TAR-less	NULL
HIV-1	NULL
promoter	NULL
with	NULL
functional	NULL
NF-kB	NULL
motifs	NULL
compared	NULL
to	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
activation	NULL
seen	NULL
in	NULL
unstimulated	NULL
cells	NULL
(	NULL
0.76-fold	NULL
)	NULL
,	NULL
whereas	NULL
PMA	NULL
induced	NULL
a	NULL
25-fold	NULL
upregulation	NULL
of	NULL
this	NULL
TAR-less	NULL
promoter	NULL
.	NULL

The	NULL
NF-kB	NULL
mutant	NULL
HIV-1	NULL
promoter	NULL
was	NULL
not	NULL
activated	NULL
by	NULL
PMA	NULL
compared	NULL
to	NULL
the	NULL
activity	NULL
seen	NULL
with	NULL
unstimulated	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
a	NULL
25-fold	NULL
level	NULL
of	NULL
activation	NULL
was	NULL
seen	NULL
with	NULL
Tat	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
PMA-induced	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
is	NULL
mediated	NULL
through	NULL
activation	NULL
of	NULL
NF-kB	NULL
in	NULL
the	NULL
HIV-1	NULL
promoter	NULL
,	NULL
whereas	NULL
with	NULL
Tat	NULL
,	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
is	NULL
through	NULL
both	NULL
TAR-dependent	NULL
and	NULL
TAR-independent	NULL
pathways	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
level	NULL
of	NULL
Tat-induced	NULL
activation	NULL
of	NULL
the	NULL
wild-type	NULL
HIV-1	NULL
LTR	NULL
is	NULL
greater	NULL
than	NULL
the	NULL
level	NULL
of	NULL
Tat-induced	NULL
activation	NULL
of	NULL
the	NULL
TAR-less	NULL
and	NULL
NF-	NULL
«	NULL
xB	NULL
mutant	NULL
HIV-1	NULL
LTR	NULL
promoters	NULL
alone	NULL
,	NULL
suggesting	NULL
that	NULL
Tat	NULL
induces	NULL
a	NULL
superactivation	NULL
of	NULL
the	NULL
wild-type	NULL
promoter	NULL
through	NULL
the	NULL
combined	NULL
effects	NULL
of	NULL
Tat	NULL
on	NULL
both	NULL
the	NULL
TAR-dependent	NULL
and	NULL
TAR-independent	NULL
activation	NULL
pathways	NULL
.	NULL

Effect	NULL
of	NULL
Go-6976	NULL
on	NULL
Tat-	NULL
,	NULL
PMA-	NULL
,	NULL
and	NULL
TNF-	NULL
«	NULL
&	NULL
-induced	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

G6-6976	NULL
is	NULL
a	NULL
synthetic	NULL
nonglycosidic	NULL
indolocarbazole	NULL
and	NULL
a	NULL
selective	NULL
inhibitor	NULL
of	NULL
PKC	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
G6-6976	NULL
at	NULL
noncytotoxic	NULL
con	NULL
6488	NULL
MHASHILKAR	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

pHIV-1	NULL
LTR-CAT	NULL
pHIV-1	NULL
LTR-ATAR-CAT	NULL
pHIV-1	NULL
LTR-mut	NULL
NFkB-CAT	NULL
300	NULL
40	NULL
40	NULL
c	NULL
0	NULL
B	NULL
F	NULL
20	NULL
@	NULL
100	NULL
20	NULL
S	NULL
J	NULL
o	NULL
LL	NULL
.	NULL

0	NULL
0	NULL
0	NULL
Tat	NULL
(	NULL
1ug/im	NULL
!	NULL
)	NULL

a	NULL
+	NULL
a	NULL
=	NULL
+	NULL
=	NULL
+	NULL
=	NULL
PMA	NULL
_	NULL
R	NULL
(	NULL
20ug/mi	NULL
)	NULL
-__	NULL
7	NULL
-	NULL
+	NULL
+	NULL
+	NULL
NE-kB	NULL
tar|	NULL
_	NULL
CAT	NULL
if	NULL
f	NULL
’	NULL
J	NULL
cat	NULL
NFkB	NULL
tar|	NULL
_	NULL
cat	NULL
A	NULL
PMA/	NULL
PMA	NULL
i	NULL
!	NULL

PMA	NULL
a	NULL
or	NULL
a	NULL
or	NULL
a	NULL
or	NULL
TNFa	NULL
TNFa	NULL
TNFa	NULL
pSVtat	NULL
pSVtat	NULL
pSVtat	NULL
B	NULL
Ne	NULL
Activity	NULL
0	NULL
0	NULL
100	NULL
57	NULL
29	NULL
5	NULL
C	NULL
Fold	NULL
Activity	NULL
-	NULL
-	NULL
-	NULL
-	NULL
_	NULL
-	NULL
259	NULL
975	NULL
14	NULL
17	NULL
0	NULL
00	NULL
28	NULL
O8	NULL
0	NULL
410	NULL
0	NULL
T	NULL
T	NULL
'	NULL
T	NULL
%	NULL
inhibition	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
>	NULL
-	NULL
623	NULL
-	NULL
>	NULL
-	NULL
100	NULL
-	NULL
>	NULL
-	NULL
6§2	NULL
-	NULL
0	NULL
-	NULL
@	NULL
0	NULL
@	NULL
e	NULL
ee	NULL
«	NULL
~	NULL
-	NULL
~	NULL
M4	NULL
eca	NULL
o	NULL
ee	NULL
o	NULL
e	NULL
ce	NULL
eee	NULL
e®	NULL
o	NULL
o	NULL
o	NULL
s	NULL
o	NULL
e	NULL
ee	NULL
0000	NULL
0	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
pSVTatulg	NULL
)	NULL
‘	NULL
0	NULL
'	NULL
0	NULL
‘	NULL
2	NULL
‘	NULL
2	NULL
‘	NULL
2	NULL
'	NULL
2	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
G1	NULL
12	NULL
+	NULL
pHIV-LTR-CAT	NULL
(	NULL
wt	NULL
)	NULL
(	NULL
1g	NULL
)	NULL
0	NULL
5	NULL
2	NULL
2	NULL
2	NULL
2	NULL
pHIV-1	NULL
LTR-CAT	NULL
(	NULL
wt	NULL
)	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
#	NULL
0	NULL
R	NULL
#	NULL
#	NULL
0	NULL
#	NULL
0	NULL
-	NULL
-	NULL
e	NULL
o-	NULL
o-	NULL
o-	NULL
o-Go6976	NULL
(	NULL
nM	NULL
)	NULL
0	NULL
0	NULL
0	NULL
10	NULL
100	NULL
300	NULL
pHIV-1	NULL
LTR-ATAR-CAT	NULL
(	NULL
6	NULL
ug	NULL
)	NULL
-	NULL
-	NULL
-	NULL
-o	NULL
&	NULL
a	NULL
+	NULL
+	NULL
-	NULL
-	NULL
-	NULL
pHIV-1	NULL
mutNFKB	NULL
LTR-CAT	NULL
(	NULL
Bug	NULL
)	NULL
|	NULL
-	NULL
-	NULL
-	NULL
00	NULL
-o	NULL
-o	NULL
=o	NULL
=o	NULL
=o	NULL
=o	NULL
+0	NULL
#	NULL
0	NULL
+0	NULL
pSVTat	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
-	NULL
-	NULL
+	NULL
+	NULL
=-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
Gosere	NULL
-	NULL
-o-	NULL
+	NULL
-o	NULL
¥	NULL
0-0	NULL
o-	NULL
4	NULL
0	NULL
o-P	NULL
E	NULL
10	NULL
100	NULL
so	NULL
so	NULL
@	NULL
%	NULL
e	NULL
@	NULL
¢	NULL
®	NULL
o	NULL
0	NULL
o	NULL
o	NULL
o	NULL
®	NULL
<	NULL
60	NULL
Coes	NULL
2	NULL
&	NULL
S	NULL
3	NULL
Cp	NULL
&	NULL
>	NULL
40	NULL
+40	NULL
5	NULL
pRSVCAT	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Go6976	NULL
(	NULL
nM	NULL
)	NULL
=	NULL
0	NULL
50	NULL
100	NULL
200	NULL
300	NULL
500	NULL
Control	NULL
-	NULL
Control	NULL
20	NULL
20	NULL
0	NULL
1	NULL
1	NULL
0	NULL
10	NULL
100	NULL
1,000	NULL
Go-6976	NULL
(	NULL
nM	NULL
)	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Tat	NULL
or	NULL
PMA-induced	NULL
CAT	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
plasmid	NULL
pHIV-1	NULL
LTR-CAT	NULL
,	NULL
pHIV-1	NULL
LTRATAR-CAT	NULL
,	NULL
or	NULL
pHIV-1	NULL
LTR-mut	NULL
NFkB-CAT	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CAT	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
untransfected	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pHIV-1	NULL
LTR	NULL
CAT	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
or	NULL
cotransfected	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
pHIV-1	NULL
LTR-CAT	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
pSVTat	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
12	NULL
)	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
0	NULL
to	NULL
300	NULL
nM	NULL
)	NULL
of	NULL
G6-6976	NULL
.	NULL

Transfections	NULL
were	NULL
done	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
of	NULL
untreated	NULL
and	NULL
G6-6976-treated	NULL
cells	NULL
were	NULL
made	NULL
48	NULL
h	NULL
posttransfection	NULL
and	NULL
analyzed	NULL
for	NULL
CAT	NULL
expression	NULL
.	NULL

wt	NULL
,	NULL
wild	NULL
type	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Influence	NULL
of	NULL
G6-6976	NULL
on	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
by	NULL
Tat	NULL
via	NULL
the	NULL
TAR-	NULL
and	NULL
NF-	NULL
«	NULL
B-dependent	NULL
,	NULL
TAR	NULL
(	NULL
alone	NULL
)	NULL
-dependent	NULL
,	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
alone	NULL
)	NULL
-dependent	NULL
activation	NULL
pathway	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
different	NULL
LTR	NULL
plasmids	NULL
by	NULL
electroporation	NULL
(	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
;	NULL
260	NULL
Volts	NULL
;	NULL
960	NULL
mF	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
with	NULL
or	NULL
without	NULL
G6-6976	NULL
[	NULL
300	NULL
nMJ	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
60	NULL
to	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
analyzed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Percent	NULL
viability	NULL
(	NULL
0	NULL
)	NULL
and	NULL
level	NULL
of	NULL
CAT	NULL
expression	NULL
(	NULL
MA	NULL
)	NULL
in	NULL
TNF-	NULL
«	NULL
-treated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
10°/10	NULL
ml	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
G6-6976-equilibrated	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
G6-6976	NULL
concentration	NULL
ranging	NULL
from	NULL
0	NULL
to	NULL
300	NULL
nM	NULL
)	NULL
and	NULL
transfected	NULL
with	NULL
10	NULL
mg	NULL
of	NULL
pHIV1	NULL
LTR-CAT	NULL
plasmid	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
grown	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
h	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
TNF-	NULL
«	NULL
(	NULL
10	NULL
ng/m1	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
another	NULL
18	NULL
h	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
percent	NULL
viability	NULL
and	NULL
CAT	NULL
expression	NULL
.	NULL

(	NULL
E	NULL
)	NULL
CAT	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
either	NULL
untransfected	NULL
or	NULL
transfected	NULL
with	NULL
plasmid	NULL
pRSV-CAT	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
increasing	NULL
final	NULL
concentrations	NULL
of	NULL
G6-6976	NULL
(	NULL
0	NULL
to	NULL
500	NULL
nM	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
PMA	NULL
(	NULL
ng/ml	NULL
)	NULL
_	NULL
0	NULL
20	NULL
20	NULL
20	NULL
20	NULL
G66976	NULL
(	NULL
nM	NULL
)	NULL
__O	NULL
0	NULL
1	NULL
10	NULL
100	NULL
fg	NULL
ge	NULL
toe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
--	NULL
NF-kB	NULL
--	NULL
Nonspecific	NULL
|	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

PMA	NULL
stimulation	NULL
of	NULL
NF-kB	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
66-6976	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
PMA	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

without	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
or	NULL
with	NULL
G6-6976	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
1	NULL
nM	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
10	NULL
nM	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
100	NULL
nM	NULL
[	NULL
final	NULL
concentration	NULL
]	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Autoradiographic	NULL
signals	NULL
of	NULL
active	NULL
NF-xB	NULL
binding	NULL
to	NULL
*°P-labeled	NULL
oligonucleotide	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
PMA-treated	NULL
cells	NULL
are	NULL
shown	NULL
.	NULL

centrations	NULL
can	NULL
inhibit	NULL
HIV-1	NULL
replication	NULL
from	NULL
latent	NULL
or	NULL
low-level	NULL
virus-producing	NULL
cells	NULL
by	NULL
physiologic	NULL
activators	NULL
such	NULL
as	NULL
TNF-a	NULL
and	NULL
IL-6	NULL
(	NULL
50	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
influence	NULL
of	NULL
G6-6976	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
gene	NULL
expression	NULL
in	NULL
CD4	NULL
*	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Tat	NULL
protein	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
little	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
is	NULL
seen	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
compared	NULL
to	NULL
the	NULL
activation	NULL
seen	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
G6-6976	NULL
(	NULL
lanes	NULL
7	NULL
through	NULL
12	NULL
)	NULL
,	NULL
a	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
is	NULL
seen	NULL
,	NULL
with	NULL
maximal	NULL
inhibition	NULL
occurring	NULL
at	NULL
300	NULL
nM	NULL
G6-6976	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
G6-6976	NULL
on	NULL
Tat	NULL
and	NULL
PMA-induced	NULL
activation	NULL
of	NULL
was	NULL
studied	NULL
by	NULL
examining	NULL
the	NULL
level	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
CAT	NULL
gene	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
different	NULL
pHIV-1	NULL
LTR-CAT	NULL
reporter	NULL
plasmids	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
with	NULL
the	NULL
wild-type	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
,	NULL
G8-6976	NULL
inhibited	NULL
Tat-induced	NULL
transactivation	NULL
by	NULL
62.3	NULL
%	NULL
.	NULL

With	NULL
the	NULL
TAR	NULL
-less	NULL
HIV-1	NULL
promoter	NULL
,	NULL
where	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
is	NULL
mediated	NULL
through	NULL
activation	NULL
of	NULL
NF-kB	NULL
alone	NULL
,	NULL
G6-6976	NULL
inhibited	NULL
Tat-induced	NULL
transactivation	NULL
completely	NULL
.	NULL

Using	NULL
the	NULL
pHIV-1	NULL
LTR-mut-NF-	NULL
«	NULL
kB-CAT	NULL
reporter	NULL
in	NULL
which	NULL
the	NULL
NF-kB	NULL
motifs	NULL
are	NULL
mutated	NULL
and	NULL
in	NULL
which	NULL
only	NULL
TAR-dependent	NULL
LTR	NULL
activation	NULL
is	NULL
measured	NULL
,	NULL
G6-6976	NULL
inhibited	NULL
65.2	NULL
%	NULL
of	NULL
Tat-induced	NULL
transactivation	NULL
of	NULL
the	NULL
mutant	NULL
LTR	NULL
.	NULL

Thus	NULL
,	NULL
inhibited	NULL
the	NULL
Tat-mediated	NULL
TAR-independent	NULL
LTR	NULL
activation	NULL
pathway	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
for	NULL
12	NULL
h	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

G6-6976	NULL
treatment	NULL
inhibited	NULL
PMA-induced	NULL
transactivation	NULL
of	NULL
wild-type	NULL
,	NULL
TAR-less	NULL
,	NULL
and	NULL
mutant	NULL
NF-	NULL
«	NULL
B	NULL
LTRs	NULL
by	NULL
97	NULL
,	NULL
98	NULL
,	NULL
and	NULL
0	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
G6-6976	NULL
on	NULL
the	NULL
TNF-	NULL
«	NULL
-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
also	NULL
studied	NULL
by	NULL
examining	NULL
the	NULL
level	NULL
of	NULL
wild-type	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
CAT	NULL
gene	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
TNF-	NULL
«	NULL
and	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
pHIV-1	NULL
LTR-CAT	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1D	NULL
,	NULL
G6-6976	NULL
also	NULL
inhib-	NULL
ANTI-HIV-1	NULL
PHARMACOLOGIC-GENETIC	NULL
STRATEGY	NULL
-	NULL
6489	NULL
ited	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
by	NULL
TNF-a	NULL
with	NULL
a	NULL
dose-response	NULL
curve	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
Tat	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
G6-6976	NULL
was	NULL
not	NULL
cytotoxic	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
and	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter-driven	NULL
CAT	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1E	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
G6-6976	NULL
on	NULL
PMA-induced	NULL
NF-KB	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
effects	NULL
of	NULL
G6-6976	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
directly	NULL
,	NULL
the	NULL
level	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
xB	NULL
was	NULL
determined	NULL
by	NULL
EMSA	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
treated	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
G6-6976	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
the	NULL
level	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
xB	NULL
was	NULL
reduced	NULL
to	NULL
the	NULL
unstimulated	NULL
level	NULL
following	NULL
treatment	NULL
of	NULL
the	NULL
stimulated	NULL
cells	NULL
with	NULL
G6-6976	NULL
at	NULL
as	NULL
low	NULL
as	NULL
1	NULL
nM	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
G6-6976	NULL
is	NULL
a	NULL
potent	NULL
NF-kB	NULL
inhibitor	NULL
and	NULL
establish	NULL
a	NULL
site	NULL
of	NULL
antiviral	NULL
action	NULL
of	NULL
the	NULL
compound	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
G6-6976	NULL
is	NULL
similar	NULL
to	NULL
PTX	NULL
,	NULL
which	NULL
was	NULL
previously	NULL
established	NULL
as	NULL
an	NULL
NF-kB	NULL
inhibitor	NULL
and	NULL
which	NULL
also	NULL
inhibited	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
and	NULL
virus	NULL
replication	NULL
(	NULL
5	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
G6-6976	NULL
and	NULL
the	NULL
Tat	NULL
inhibitor	NULL
Ro24-7429	NULL
in	NULL
combination	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
.	NULL

Previous	NULL
studies	NULL
demonstrated	NULL
that	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PTX	NULL
in	NULL
combination	NULL
with	NULL
Ro24-7429	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
Tat	NULL
function	NULL
,	NULL
resulted	NULL
in	NULL
cooperative	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
inhibition	NULL
by	NULL
Ro24-7429	NULL
is	NULL
not	NULL
known	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
combined	NULL
effect	NULL
of	NULL
G6-6976	NULL
and	NULL
Ro24-7429	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
CAT	NULL
gene	NULL
expression	NULL
was	NULL
examined	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
pHIV-1	NULL
LTR-CAT	NULL
and	NULL
pSV	NULL
Tat	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
different	NULL
combinations	NULL
of	NULL
G6-6976	NULL
120	NULL
100	NULL
80	NULL
60	NULL
%	NULL
CAT	NULL
Activity	NULL
40	NULL
20	NULL
0	NULL
10	NULL
30	NULL
100	NULL
300	NULL
%	NULL
CAT	NULL
Activity	NULL
fer	NULL
6	NULL
frr	NULL
___	NULL
_c	NULL
___	NULL
}	NULL
0	NULL
10	NULL
30	NULL
100	NULL
300	NULL
[	NULL
Drug	NULL
Concentration	NULL
]	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
G6-6976	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
with	NULL
Ro24-7429	NULL
(	NULL
A	NULL
)	NULL
or	NULL
PTX	NULL
(	NULL
B	NULL
)	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
gene	NULL
expression	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
either	NULL
untransfected	NULL
or	NULL
cotransfected	NULL
with	NULL
an	NULL
equimolar	NULL
concentrations	NULL
of	NULL
pHIV-1	NULL
LTR	NULL
CAT	NULL
and	NULL
pSVTat	NULL
(	NULL
2	NULL
mg	NULL
of	NULL
each	NULL
)	NULL
,	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
either	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
test	NULL
drug	NULL
for	NULL
48	NULL
h	NULL
prior	NULL
to	NULL
harvesting	NULL
of	NULL
cell	NULL
lysates	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Percent	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
either	NULL
Ro24-7429	NULL
(	NULL
nanomolar	NULL
;	NULL
O	NULL
)	NULL
,	NULL
G6-6976	NULL
(	NULL
nanomolar	NULL
;	NULL
D	NULL
)	NULL
,	NULL
or	NULL
Ro24-7429	NULL
plus	NULL
G6-6976	NULL
(	NULL
@	NULL
I	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Percent	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
either	NULL
PTX	NULL
(	NULL
micromolar	NULL
;	NULL
O	NULL
)	NULL
,	NULL
G6-6976	NULL
(	NULL
nanomolar	NULL
;	NULL
D	NULL
)	NULL
,	NULL
or	NULL
PTX	NULL
plus	NULL
G6-6976	NULL
(	NULL
RN	NULL
.	NULL

6490	NULL
MHASHILKAR	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
p24	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

p24	NULL
(	NULL
ng/ml	NULL
)	NULL
Days	NULL
Post-infection	NULL
J.	NULL
ViRoL	NULL
.	NULL

p24	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

p24	NULL
(	NULL
ng/ml	NULL
)	NULL
Days	NULL
Post-infection	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
on	NULL
HIV-1	NULL
infection	NULL
in	NULL
human	NULL
CD4*	NULL
SupT	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
PBMCs	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
SupT	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
either	NULL
grown	NULL
in	NULL
untreated	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
0	NULL
)	NULL
or	NULL
equilibrated	NULL
in	NULL
300	NULL
M	NULL
PTX	NULL
(	NULL
MD	NULL
,	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
0	NULL
)	NULL
,	NULL
or	NULL
300	NULL
M	NULL
PTX	NULL
plus	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
(	NULL
MOI	NULL
of	NULL
0.5	NULL
)	NULL
with	NULL
either	NULL
(	NULL
A	NULL
)	NULL
or	NULL
primary	NULL
isolate	NULL
1	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
cell-free	NULL
p24	NULL
levels	NULL
were	NULL
recorded	NULL
on	NULL
alternate	NULL
days	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
PBMCs	NULL
were	NULL
stimulated	NULL
with	NULL
OKT3	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
were	NULL
either	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-2	NULL
(	NULL
0	NULL
)	NULL
or	NULL
additionally	NULL
equilibrated	NULL
in	NULL
300	NULL
M	NULL
PTX	NULL
(	NULL
ID	NULL
,	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
0	NULL
)	NULL
,	NULL
or	NULL
300	NULL
M	NULL
PTX	NULL
plus	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
(	NULL
MOI	NULL
of	NULL
0.5	NULL
)	NULL
with	NULL
primary	NULL
isolate	NULL
1	NULL
(	NULL
C	NULL
)	NULL
or	NULL
2	NULL
(	NULL
D	NULL
)	NULL
,	NULL
and	NULL
cell-free	NULL
p24	NULL
levels	NULL
were	NULL
recorded	NULL
on	NULL
alternate	NULL
days	NULL
.	NULL

and/or	NULL
Ro24-7429	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
significant	NULL
inhibition	NULL
of	NULL
CAT	NULL
gene	NULL
activity	NULL
is	NULL
seen	NULL
.	NULL

Quantitative	NULL
analysis	NULL
of	NULL
the	NULL
CAT	NULL
assay	NULL
demonstrated	NULL
that	NULL
markedly	NULL
lower	NULL
concentrations	NULL
of	NULL
the	NULL
compounds	NULL
(	NULL
10	NULL
nM	NULL
G6-6976	NULL
and	NULL
Ro24-7429	NULL
)	NULL
which	NULL
individually	NULL
did	NULL
not	NULL
cause	NULL
significant	NULL
inhibition	NULL
led	NULL
to	NULL
93	NULL
%	NULL
reduction	NULL
of	NULL
CAT	NULL
gene	NULL
activity	NULL
when	NULL
used	NULL
in	NULL
combination	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
NF-kB	NULL
inhibitor	NULL
G6-6976	NULL
and	NULL
the	NULL
Tat	NULL
inhibitor	NULL
Ro24-7429	NULL
in	NULL
combination	NULL
cooperatively	NULL
down-regulate	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Effect	NULL
of	NULL
two	NULL
NF-KB	NULL
inhibitors	NULL
in	NULL
combination	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
.	NULL

The	NULL
combined	NULL
effect	NULL
of	NULL
G6-6976	NULL
and	NULL
PTX	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
CAT	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
examined	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
with	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
cotransfected	NULL
with	NULL
pHIV-1	NULL
LTR-CAT	NULL
and	NULL
pSVTat	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
PTX	NULL
and/or	NULL
G6-6976	NULL
,	NULL
significant	NULL
inhibition	NULL
of	NULL
CAT	NULL
gene	NULL
activity	NULL
is	NULL
observed	NULL
.	NULL

Quantitative	NULL
analysis	NULL
of	NULL
the	NULL
CAT	NULL
assay	NULL
demonstrated	NULL
that	NULL
lower	NULL
concentrations	NULL
of	NULL
the	NULL
compounds	NULL
(	NULL
10	NULL
to	NULL
50	NULL
M	NULL
PTX	NULL
or	NULL
10	NULL
to	NULL
50	NULL
nM	NULL
G6-6976	NULL
which	NULL
individually	NULL
did	NULL
not	NULL
cause	NULL
significant	NULL
inhibition	NULL
led	NULL
to	NULL
50	NULL
to	NULL
70	NULL
%	NULL
reduction	NULL
of	NULL
CAT	NULL
gene	NULL
activity	NULL
when	NULL
used	NULL
in	NULL
combination	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
when	NULL
used	NULL
in	NULL
combination	NULL
,	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
PTX	NULL
and	NULL
G6-6976	NULL
also	NULL
cooperatively	NULL
down-regulate	NULL
,	NULL
in	NULL
a	NULL
TAR-independent	NULL
pathway	NULL
,	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
CD4*	NULL
SupT	NULL
cells	NULL
and	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
NF-KB	NULL
inhibitors	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
PTX	NULL
and	NULL
G0-6976	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
were	NULL
able	NULL
to	NULL
inhibit	NULL
HIV-1	NULL
replication	NULL
,	NULL
we	NULL
initially	NULL
performed	NULL
challenge	NULL
experiments	NULL
using	NULL
human	NULL
CD4	NULL
*	NULL
SupT	NULL
cells	NULL
and	NULL
either	NULL
a	NULL
laboratory	NULL
strain	NULL
(	NULL
II-B	NULL
)	NULL
or	NULL
an	NULL
SI	NULL
European	NULL
primary	NULL
HIV-1	NULL
isolate	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
PTX	NULL
,	NULL
G6-6976	NULL
,	NULL
or	NULL
both	NULL
drugs	NULL
overnight	NULL
prior	NULL
to	NULL
challenge	NULL
with	NULL
the	NULL
different	NULL
viruses	NULL
.	NULL

Supernatants	NULL
were	NULL
isolated	NULL
on	NULL
alternate	NULL
days	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
monitored	NULL
for	NULL
syncytium	NULL
formation	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
quantitated	NULL
for	NULL
p24	NULL
levels	NULL
.	NULL

Cells	NULL
treated	NULL
with	NULL
G6-6976	NULL
alone	NULL
gave	NULL
marked	NULL
protection	NULL
against	NULL
HIV-1	NULL
whether	NULL
the	NULL
cells	NULL
were	NULL
challenged	NULL
with	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
or	NULL
with	NULL
primary	NULL
isolate	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
protection	NULL
was	NULL
not	NULL
seen	NULL
with	NULL
PTX	NULL
alone	NULL
in	NULL
either	NULL
challenge	NULL
experiment	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
PTX	NULL
and	NULL
G6-6976	NULL
resulted	NULL
in	NULL
a	NULL
small	NULL
additional	NULL
protective	NULL
effect	NULL
on	NULL
cells	NULL
challenged	NULL
with	NULL
primary	NULL
isolate	NULL
1	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
performed	NULL
similar	NULL
HIV-1	NULL
challenge	NULL
experiments	NULL
using	NULL
PBMCs	NULL
and	NULL
two	NULL
SI	NULL
European	NULL
primary	NULL
isolates	NULL
.	NULL

Cells	NULL
treated	NULL
with	NULL
G6-6976	NULL
alone	NULL
gave	NULL
substantial	NULL
protection	NULL
against	NULL
primary	NULL
isolates	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
and	NULL
2	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

This	NULL
level	NULL
of	NULL
protection	NULL
was	NULL
not	NULL
seen	NULL
with	NULL
PTX	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
of	NULL
the	NULL
challenge	NULL
experiments	NULL
with	NULL
SupT	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
PTX	NULL
and	NULL
G6-6976	NULL
resulted	NULL
in	NULL
a	NULL
significant	NULL
improvement	NULL
in	NULL
protection	NULL
compared	NULL
to	NULL
cells	NULL
treated	NULL
with	NULL
G6-6976	NULL
alone	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
inhibition	NULL
of	NULL
virus	NULL
replication	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
correlated	NULL
well	NULL
with	NULL
their	NULL
effects	NULL
on	NULL
HIV-1	NULL
LTR-regulated	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Prolonged	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
stably	NULL
transfected	NULL
CD4*	NULL
SupT	NULL
cells	NULL
and	NULL
in	NULL
transduced	NULL
PBMCs	NULL
and	NULL
CD4*	NULL
mononuclear	NULL
cells	NULL
expressing	NULL
Anti-Tat	NULL
sFv	NULL
intrabodies	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
NF-KB	NULL
inhibitors	NULL
.	NULL

Since	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
NF-kB	NULL
and	NULL
Tat	NULL
inhibitors	NULL
results	NULL
in	NULL
cooperative	NULL
down-regulation	NULL
of	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
and	NULL
references	NULL
6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
these	NULL
observations	NULL
suggested	NULL
that	NULL
a	NULL
combined	NULL
genetic	NULL
and	NULL
pharmacologic	NULL
treatment	NULL
strategy	NULL
might	NULL
result	NULL
in	NULL
a	NULL
more	NULL
durable	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
40	NULL
p24	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

to	NULL
©	NULL
10	NULL
2	NULL
30	NULL
40	NULL
50	NULL
Days	NULL
Post-infection	NULL
€	NULL
&	NULL
£	NULL
x	NULL
o	NULL
o	NULL
.	NULL

2	NULL
Days	NULL
Post-infection	NULL
ANTI-HIV-1	NULL
PHARMACOLOGIC-GENETIC	NULL
STRATEGY	NULL
6491	NULL
C	NULL
50	NULL
40	NULL
E	NULL
30	NULL
2	NULL
3	NULL
%	NULL
20	NULL
10	NULL
0	NULL
<	NULL
0	NULL
3	NULL
6	NULL
9	NULL
12	NULL
15	NULL
18	NULL
Days	NULL
Post-infection	NULL
D	NULL
50	NULL
40	NULL
€	NULL
so	NULL
?	NULL

jes	NULL
m.	NULL
20	NULL
0	NULL
3	NULL
6	NULL
9	NULL
12	NULL
15	NULL
18	NULL
Days	NULL
Post-infection	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Effects	NULL
of	NULL
NF-B	NULL
inhibitors	NULL
on	NULL
HIV-1	NULL
infection	NULL
in	NULL
stably	NULL
transfected	NULL
CD4*	NULL
SupT	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
transduced	NULL
PBMCs	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
expressing	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

SupT-sFviat1Ck	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
either	NULL
grown	NULL
in	NULL
untreated	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
C	NULL
)	NULL
or	NULL
equilibrated	NULL
in	NULL
300	NULL
M	NULL
PTX	NULL
(	NULL
@	NULL
I	NULL
)	NULL
,	NULL
or	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
O	NULL
)	NULL
,	NULL
or	NULL
300	NULL
M	NULL
PTX	NULL
plus	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
(	NULL
MOI	NULL
of	NULL
0.5	NULL
)	NULL
with	NULL
either	NULL
(	NULL
A	NULL
)	NULL
or	NULL
primary	NULL
isolate	NULL
1	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
cell-free	NULL
p24	NULL
levels	NULL
were	NULL
recorded	NULL
on	NULL
alternate	NULL
days	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
Transduced	NULL
PBMCs	NULL
(	NULL
C	NULL
)	NULL
or	NULL
CD4*	NULL
mononuclear	NULL
cells	NULL
(	NULL
D	NULL
)	NULL
(	NULL
squares	NULL
,	NULL
LN-vector	NULL
supernatants	NULL
;	NULL
circles	NULL
,	NULL
LN-sFvtat1Ck	NULL
supernatants	NULL
)	NULL
were	NULL
either	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-2	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
equilibrated	NULL
in	NULL
IL-2-RPMI	NULL
1640	NULL
medium	NULL
with	NULL
300	NULL
M	NULL
PTX	NULL
plus	NULL
300	NULL
nM	NULL
G6-6976	NULL
(	NULL
closed	NULL
symbols	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
(	NULL
MOI	NULL
of	NULL
0.3	NULL
)	NULL
with	NULL
SI	NULL
primary	NULL
isolate	NULL
2	NULL
(	NULL
C	NULL
)	NULL
or	NULL
1	NULL
(	NULL
D	NULL
)	NULL
,	NULL
and	NULL
cell-free	NULL
p24	NULL
levels	NULL
were	NULL
recorded	NULL
on	NULL
alternate	NULL
days	NULL
.	NULL

an	NULL
anti-	NULL
Tat	NULL
sFv	NULL
intrabody	NULL
,	NULL
termed	NULL
sFvtat1Ck	NULL
,	NULL
which	NULL
is	NULL
directed	NULL
against	NULL
the	NULL
N-terminal	NULL
activation	NULL
domain	NULL
of	NULL
Tat	NULL
protein	NULL
could	NULL
protect	NULL
cells	NULL
from	NULL
HIV-1	NULL
challenge	NULL
when	NULL
stably	NULL
expressed	NULL
in	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
influence	NULL
of	NULL
these	NULL
two	NULL
NF-kB	NULL
inhibitors	NULL
on	NULL
HIV-1	NULL
infection	NULL
in	NULL
anti-Tat	NULL
sFv	NULL
intrabody-expressing	NULL
cells	NULL
was	NULL
examined	NULL
.	NULL

Stable	NULL
SupT-sFvtat1Ck	NULL
and	NULL
control	NULL
SupT-vector	NULL
cells	NULL
were	NULL
challenged	NULL
with	NULL
either	NULL
HIV-1	NULL
;	NULL
;	NULL
or	NULL
SI	NULL
primary	NULL
isolate	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
or	NULL
B	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

With	NULL
the	NULL
control	NULL
SupT-vector-infected	NULL
cells	NULL
,	NULL
large	NULL
number	NULL
of	NULL
syncytia	NULL
started	NULL
appearing	NULL
on	NULL
days	NULL
4	NULL
to	NULL
5	NULL
,	NULL
and	NULL
p24	NULL
release	NULL
had	NULL
peaked	NULL
on	NULL
day	NULL
12	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Syncytium	NULL
formation	NULL
was	NULL
delayed	NULL
in	NULL
the	NULL
anti-Tat	NULL
sFv	NULL
intrabody-expressing	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
drugs	NULL
until	NULL
around	NULL
day	NULL
20	NULL
postinfection	NULL
,	NULL
and	NULL
subsequently	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
p24	NULL
level	NULL
was	NULL
observed	NULL
in	NULL
both	NULL
laboratory	NULL
strain-	NULL
and	NULL
primary	NULL
isolate-infected	NULL
SupT-sFvtat1Ck	NULL
cells	NULL
at	NULL
around	NULL
day	NULL
25	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
PTX	NULL
alone	NULL
(	NULL
300	NULL
uM	NULL
)	NULL
,	NULL
p24	NULL
levels	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
in	NULL
the	NULL
untreated	NULL
infected	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
G6-6976	NULL
either	NULL
alone	NULL
(	NULL
300	NULL
nM	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
PTX	NULL
(	NULL
300	NULL
M	NULL
)	NULL
showed	NULL
significantly	NULL
fewer	NULL
syncytia	NULL
or	NULL
no	NULL
syncytia	NULL
until	NULL
day	NULL
30	NULL
or	NULL
40	NULL
,	NULL
respectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

After	NULL
around	NULL
25	NULL
to	NULL
30	NULL
days	NULL
,	NULL
the	NULL
SupT-sFvtat1	NULL
Ck	NULL
cells	NULL
that	NULL
were	NULL
grown	NULL
in	NULL
G6-6976-containing	NULL
medium	NULL
start	NULL
to	NULL
show	NULL
increasing	NULL
levels	NULL
of	NULL
p24	NULL
,	NULL
whereas	NULL
cells	NULL
grown	NULL
in	NULL
PTX-plus-G6-6976	NULL
medium	NULL
showed	NULL
protection	NULL
against	NULL
viral	NULL
infection	NULL
for	NULL
up	NULL
to	NULL
45	NULL
days	NULL
postinfection	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
addition	NULL
of	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
to	NULL
the	NULL
anti-Tat	NULL
sFv	NULL
intrabody-expressing	NULL
cells	NULL
substantially	NULL
prolonged	NULL
the	NULL
protection	NULL
against	NULL
HIV-1	NULL
challenge	NULL
seen	NULL
with	NULL
the	NULL
anti-	NULL
Tat	NULL
sFv	NULL
intrabody	NULL
alone	NULL
.	NULL

Two	NULL
additional	NULL
HIV-1	NULL
challenge	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
PBMCs	NULL
and	NULL
purified	NULL
CD4	NULL
*	NULL
mononuclear	NULL
cells	NULL
that	NULL
were	NULL
transduced	NULL
with	NULL
an	NULL
empty	NULL
LN	NULL
retroviral	NULL
vector	NULL
or	NULL
with	NULL
the	NULL
same	NULL
vector	NULL
containing	NULL
the	NULL
sFvtat1Ck	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
an	NULL
internal	NULL
cytomegalovirus	NULL
immediate-early	NULL
promoter	NULL
.	NULL

After	NULL
G418	NULL
selection	NULL
,	NULL
the	NULL
bulk-transduced	NULL
PBMCs	NULL
were	NULL
challenged	NULL
with	NULL
SI	NULL
primary	NULL
isolate	NULL
2	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
PTX	NULL
(	NULL
300	NULL
uM	NULL
)	NULL
plus	NULL
G6-6976	NULL
(	NULL
300	NULL
nM	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
vector-transduced	NULL
PBMCs	NULL
were	NULL
significantly	NULL
protected	NULL
from	NULL
HIV-1	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PTX	NULL
plus	NULL
G6-6976	NULL
compared	NULL
to	NULL
the	NULL
level	NULL
of	NULL
p24	NULL
seen	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
drugs	NULL
,	NULL
where	NULL
cell-free	NULL
p24	NULL
was	NULL
first	NULL
observed	NULL
3	NULL
days	NULL
postinfection	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
sFvtat1Ck-transduced	NULL
PBMCs	NULL
were	NULL
significantly	NULL
protected	NULL
from	NULL
HIV-1	NULL
compared	NULL
to	NULL
the	NULL
level	NULL
of	NULL
p24	NULL
seen	NULL
in	NULL
the	NULL
vector	NULL
transduced	NULL
PBMCs	NULL
.	NULL

Moreover	NULL
,	NULL
for	NULL
PBMCs	NULL
that	NULL
were	NULL
transduced	NULL
with	NULL
the	NULL
sFvtat1Ck	NULL
gene	NULL
and	NULL
treated	NULL
with	NULL
the	NULL
two	NULL
NF-kB	NULL
inhibitors	NULL
,	NULL
no	NULL
cell-free	NULL
p24	NULL
was	NULL
detected	NULL
for	NULL
the	NULL
entire	NULL
18-day	NULL
experiment	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
a	NULL
similar	NULL
protective	NULL
effect	NULL
of	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
on	NULL
the	NULL
vector-	NULL
and	NULL
sFvtat1Ck-transduced	NULL
CD4*	NULL
mononuclear	NULL
cells	NULL
that	NULL
were	NULL
challenged	NULL
with	NULL
SI	NULL
primary	NULL
isolate	NULL
1	NULL
was	NULL
observed	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
studies	NULL
demonstrate	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
can	NULL
prolong	NULL
the	NULL
antiviral	NULL
action	NULL
of	NULL
either	NULL
class	NULL
of	NULL
these	NULL
agents	NULL
alone	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
demonstrate	NULL
that	NULL
the	NULL
PKC	NULL
inhibitors	NULL
PTX	NULL
and	NULL
G6-6976	NULL
act	NULL
cooperatively	NULL
to	NULL
inhibit	NULL
Tat	NULL
6492	NULL
MHASHILKAR	NULL
ET	NULL
AL	NULL
.	NULL

NFKB	NULL
NFkB	NULL
motif	NULL
TAR	NULL
motif	NULL
HIV	NULL
TNF	NULL
Gene	NULL
Gene	NULL
Tat	NULL
\	NULL
TNF	NULL
__	NULL
TNF	NULL
«	NULL
Promoter	NULL
Nucleus	NULL
Tat	NULL
transport	NULL
$	NULL
1	NULL
[	NULL
Tat	NULL
NFkB	NULL
t	NULL
Protein	NULL
PTX	NULL
,	NULL
assare	NULL
[	NULL
~-A1	NULL
[	NULL
PK	NULL
H	NULL
“	NULL
Cytoplasm	NULL
TNF	NULL
Receptor-x	NULL
V	NULL
mediated	NULL
-TNF	NULL
uptake	NULL
v	NULL
S	NULL
Tat	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Schematic	NULL
description	NULL
of	NULL
Tat-	NULL
and	NULL
NF-	NULL
«	NULL
B-induced	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Steps	NULL
of	NULL
the	NULL
TAR-dependent	NULL
and	NULL
TAR-independent	NULL
pathways	NULL
of	NULL
Tat	NULL
action	NULL
in	NULL
superactivating	NULL
the	NULL
HIV-1	NULL
promoter	NULL
function	NULL
are	NULL
indicated	NULL
by	NULL
numerals	NULL
.	NULL

The	NULL
HIV-1	NULL
LTR	NULL
sequence	NULL
is	NULL
shown	NULL
at	NULL
the	NULL
top	NULL
left	NULL
,	NULL
and	NULL
the	NULL
TNF	NULL
promoter	NULL
is	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
.	NULL

Steps	NULL
:	NULL
1	NULL
,	NULL
production	NULL
of	NULL
Tat	NULL
protein	NULL
from	NULL
the	NULL
fat	NULL
gene	NULL
and	NULL
its	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
via	NULL
binding	NULL
to	NULL
TAR	NULL
;	NULL
2	NULL
,	NULL
upregulation	NULL
of	NULL
the	NULL
TNF	NULL
promoter	NULL
by	NULL
intracellular	NULL
Tat	NULL
protein	NULL
or	NULL
by	NULL
uptake	NULL
of	NULL
Tat	NULL
protein	NULL
released	NULL
from	NULL
HIV-1-infected	NULL
cells	NULL
;	NULL
3	NULL
,	NULL
elevation	NULL
of	NULL
TNF	NULL
mRNA	NULL
levels	NULL
,	NULL
translation	NULL
,	NULL
cellular	NULL
secretion	NULL
,	NULL
and	NULL
receptor-mediated	NULL
uptake	NULL
of	NULL
TNF	NULL
,	NULL
and	NULL
PKC-mediated	NULL
release	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
;	NULL
4	NULL
,	NULL
interaction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
its	NULL
motifs	NULL
in	NULL
the	NULL
LTR	NULL
and	NULL
TNF	NULL
promoter	NULL
,	NULL
leading	NULL
to	NULL
Tat/NF-	NULL
«	NULL
B-mediated	NULL
superactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

The	NULL
anti-Tat	NULL
sFv	NULL
intrabody	NULL
sFvTat1Ck	NULL
blocks	NULL
nuclear	NULL
translocation	NULL
of	NULL
Tat	NULL
,	NULL
and	NULL
the	NULL
PKC	NULL
inhibitors	NULL
PTX	NULL
and	NULL
G6-6976	NULL
block	NULL
release	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Extracellular	NULL
mediated	NULL
HIV-1	NULL
LTR	NULL
transactivation	NULL
by	NULL
exerting	NULL
their	NULL
combined	NULL
effects	NULL
on	NULL
the	NULL
TAR-independent	NULL
LTR	NULL
activation	NULL
pathway	NULL
which	NULL
is	NULL
mediated	NULL
through	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

This	NULL
inhibitory	NULL
effect	NULL
is	NULL
also	NULL
seen	NULL
in	NULL
HIV-1	NULL
challenge	NULL
experiments	NULL
,	NULL
where	NULL
the	NULL
protection	NULL
against	NULL
HIV-1	NULL
was	NULL
more	NULL
durable	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
combined	NULL
PKC	NULL
inhibitors	NULL
than	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
inhibitor	NULL
alone	NULL
.	NULL

Moreover	NULL
,	NULL
when	NULL
these	NULL
agents	NULL
were	NULL
evaluated	NULL
together	NULL
with	NULL
either	NULL
anti-	NULL
Tat	NULL
sFv	NULL
intrabody-expressing	NULL
stably	NULL
transfected	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
transduced	NULL
PBMCs	NULL
and	NULL
CD4	NULL
*	NULL
mononuclear	NULL
cells	NULL
,	NULL
a	NULL
even	NULL
greater	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
was	NULL
observed	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
results	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
a	NULL
combined	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
strategy	NULL
that	NULL
blocks	NULL
simultaneously	NULL
both	NULL
the	NULL
TAR-dependent	NULL
and	NULL
NF-xB-dependent	NULL
Tat	NULL
activation	NULL
pathways	NULL
may	NULL
be	NULL
of	NULL
value	NULL
in	NULL
the	NULL
clinical	NULL
setting	NULL
.	NULL

The	NULL
mechanisms	NULL
by	NULL
which	NULL
Tat	NULL
mediates	NULL
LTR	NULL
transactivation	NULL
are	NULL
complex	NULL
.	NULL

Previous	NULL
studies	NULL
and	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
demonstrate	NULL
that	NULL
Tat	NULL
can	NULL
activate	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
through	NULL
both	NULL
TAR-dependent	NULL
and	NULL
NF-	NULL
«	NULL
B-dependent	NULL
pathways	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Tat	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
transactivate	NULL
several	NULL
cytokine	NULL
genes	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
48a	NULL
)	NULL
.	NULL

Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
TNF-a	NULL
promoter	NULL
occurs	NULL
through	NULL
activation	NULL
of	NULL
NF-kB	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
activates	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
in	NULL
a	NULL
TAR-independent	NULL
manner	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
results	NULL
in	NULL
transactivation	NULL
of	NULL
TNF-	NULL
«	NULL
and	NULL
other	NULL
cytokine	NULL
promoters	NULL
and	NULL
thereby	NULL
establishes	NULL
an	NULL
auto-up-regulatory	NULL
loop	NULL
for	NULL
superactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
and	NULL
reference	NULL
7	NULL
)	NULL
.	NULL

The	NULL
cooperative	NULL
effect	NULL
of	NULL
PTX	NULL
and	NULL
G6-6976	NULL
on	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
was	NULL
unexpected	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
PTX	NULL
results	NULL
in	NULL
inhibition	NULL
of	NULL
both	NULL
PKC-	NULL
and	NULL
PKA-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
that	NULL
both	NULL
TNF-	NULL
«	NULL
-	NULL
and	NULL
PMA-induced	NULL
J.	NULL
ViRoL	NULL
.	NULL

activations	NULL
of	NULL
NF-kB	NULL
are	NULL
catalyzed	NULL
predominantly	NULL
by	NULL
PKC	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
G6-6976	NULL
is	NULL
a	NULL
selective	NULL
inhibitor	NULL
of	NULL
PKC	NULL
and	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
TNF-	NULL
«	NULL
-induced	NULL
activation	NULL
of	NULL
viral	NULL
transcription	NULL
from	NULL
latent	NULL
or	NULL
low-level	NULL
virus-producing	NULL
chronically	NULL
infected	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
present	NULL
study	NULL
demonstrates	NULL
that	NULL
like	NULL
PTX	NULL
,	NULL
G6-6976	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
NF-kB	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
these	NULL
drugs	NULL
have	NULL
overlapping	NULL
sites	NULL
of	NULL
action	NULL
on	NULL
PKC	NULL
and	NULL
NF-	NULL
B	NULL
,	NULL
they	NULL
appear	NULL
to	NULL
have	NULL
an	NULL
additive	NULL
,	NULL
if	NULL
not	NULL
cooperative	NULL
,	NULL
effect	NULL
as	NULL
inhibitors	NULL
of	NULL
both	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
and	NULL
virus	NULL
replication	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
determine	NULL
if	NULL
other	NULL
cellular	NULL
kinases	NULL
with	NULL
nonoverlapping	NULL
sites	NULL
of	NULL
action	NULL
are	NULL
inhibited	NULL
by	NULL
these	NULL
two	NULL
agents	NULL
.	NULL

A	NULL
previous	NULL
study	NULL
demonstrated	NULL
that	NULL
superactivation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
cooperative	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Tat	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PTX	NULL
and	NULL
Ro24-7429	NULL
resulted	NULL
in	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
LTR-regulated	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
these	NULL
two	NULL
drugs	NULL
in	NULL
combination	NULL
,	NULL
at	NULL
concentrations	NULL
that	NULL
alone	NULL
did	NULL
not	NULL
significantly	NULL
influence	NULL
viral	NULL
promoter	NULL
activity	NULL
,	NULL
was	NULL
far	NULL
more	NULL
than	NULL
additive	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
a	NULL
cooperative	NULL
inhibition	NULL
of	NULL
G6-6976	NULL
and	NULL
Ro24-7429	NULL
on	NULL
superactivation	NULL
of	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

As	NULL
with	NULL
the	NULL
PTX-Ro24-7429	NULL
study	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
demonstrate	NULL
that	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
G6-6976	NULL
and	NULL
Ro24-7429	NULL
in	NULL
combination	NULL
,	NULL
at	NULL
concentrations	NULL
that	NULL
alone	NULL
did	NULL
not	NULL
significantly	NULL
influence	NULL
viral	NULL
promoter	NULL
activity	NULL
,	NULL
was	NULL
far	NULL
more	NULL
than	NULL
additive	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
combined	NULL
pharmacologic	NULL
approaches	NULL
to	NULL
simultaneously	NULL
target	NULL
both	NULL
NF-kB	NULL
and	NULL
Tat	NULL
were	NULL
extended	NULL
to	NULL
evaluate	NULL
a	NULL
combined	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
strategy	NULL
that	NULL
targets	NULL
both	NULL
NF-kB	NULL
and	NULL
Tat	NULL
.	NULL

Indeed	NULL
,	NULL
when	NULL
these	NULL
two	NULL
PKC	NULL
inhibitors	NULL
were	NULL
evaluated	NULL
together	NULL
with	NULL
anti-	NULL
Tat	NULL
sFv	NULL
intrabody-expressing	NULL
cells	NULL
,	NULL
either	NULL
stably	NULL
transfected	NULL
CD4*	NULL
T	NULL
cells	NULL
or	NULL
transduced	NULL
PBMCs	NULL
,	NULL
a	NULL
greater	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
was	NULL
observed	NULL
than	NULL
with	NULL
either	NULL
the	NULL
combined	NULL
PKC	NULL
inhibitors	NULL
alone	NULL
or	NULL
the	NULL
anti-tat	NULL
sFv	NULL
intrabody-expressing	NULL
cells	NULL
alone	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
although	NULL
HIV-1	NULL
infection	NULL
eventually	NULL
spread	NULL
in	NULL
the	NULL
cell	NULL
culture	NULL
in	NULL
these	NULL
studies	NULL
,	NULL
these	NULL
experiments	NULL
were	NULL
performed	NULL
at	NULL
high	NULL
MOIs	NULL
(	NULL
0.5	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
this	NULL
novel	NULL
combination	NULL
of	NULL
anti-Tat	NULL
sFv	NULL
intrabody	NULL
and	NULL
NF-KB	NULL
inhibitors	NULL
may	NULL
have	NULL
even	NULL
greater	NULL
therapeutic	NULL
value	NULL
against	NULL
HIV-1	NULL
in	NULL
vivo	NULL
where	NULL
exposure	NULL
of	NULL
CD4*	NULL
cells	NULL
to	NULL
low	NULL
MOIs	NULL
may	NULL
occur	NULL
.	NULL

Interestingly	NULL
,	NULL
immune	NULL
hyperactivation	NULL
of	NULL
HIV-l-infected	NULL
primary	NULL
T-cells	NULL
via	NULL
CD3	NULL
and	NULL
CD28	NULL
receptors	NULL
has	NULL
been	NULL
dem-onstrated	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
Tat	NULL
protein	NULL
recapitulates	NULL
this	NULL
phenotype	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
increased	NULL
IL-2	NULL
secretion	NULL
in	NULL
response	NULL
to	NULL
costimulation	NULL
with	NULL
CD3	NULL
plus	NULL
CD28	NULL
(	NULL
48a	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
anti-	NULL
Tat	NULL
sFv	NULL
intrabodies	NULL
are	NULL
not	NULL
secreted	NULL
or	NULL
released	NULL
from	NULL
the	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
intracellular	NULL
antibodies	NULL
can	NULL
inhibit	NULL
both	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
secretion	NULL
following	NULL
T-cell	NULL
activation	NULL
via	NULL
the	NULL
CD3	NULL
and	NULL
CD28	NULL
receptors	NULL
and	NULL
the	NULL
release	NULL
of	NULL
Tat	NULL
into	NULL
the	NULL
cultures	NULL
that	NULL
can	NULL
result	NULL
in	NULL
Tat-mediated	NULL
transcellular	NULL
transactivation	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
TNF-	NULL
«	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
the	NULL
anti-Tat	NULL
sFv	NULL
intrabodies	NULL
could	NULL
result	NULL
in	NULL
the	NULL
combined	NULL
down-regulation	NULL
of	NULL
immune	NULL
hyperactivation	NULL
of	NULL
HIV-1-infected	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
the	NULL
auto-up-regulatory	NULL
loop	NULL
for	NULL
Tat-mediated	NULL
superactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
and	NULL
the	NULL
transcellular	NULL
transactivation	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
neighboring	NULL
noninfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
studies	NULL
demonstrate	NULL
that	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Tat	NULL
in	NULL
combination	NULL
result	NULL
in	NULL
a	NULL
more	NULL
profound	NULL
and	NULL
durable	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
than	NULL
inhibitors	NULL
of	NULL
either	NULL
NF-	NULL
«	NULL
B	NULL
or	NULL
Tat	NULL
alone	NULL
.	NULL

Such	NULL
combination	NULL
of	NULL
pharmacologic	NULL
and	NULL
genetic	NULL
approaches	NULL
may	NULL
enhance	NULL
the	NULL
efficacy	NULL
and/or	NULL
reduce	NULL
the	NULL
toxic	NULL
effect	NULL
of	NULL
individual	NULL
molecules	NULL
;	NULL
they	NULL
may	NULL
also	NULL
minimize	NULL
or	NULL
retard	NULL
the	NULL
emergence	NULL
of	NULL
drug-resistant	NULL
or	NULL
escape	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
variants	NULL
of	NULL
HIV-1	NULL
.	NULL

In	NULL
future	NULL
clinical	NULL
gene	NULL
therapy	NULL
trials	NULL
that	NULL
target	NULL
the	NULL
Tat	NULL
protein	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
pharmacologic	NULL
arm	NULL
,	NULL
particularly	NULL
when	NULL
directed	NULL
to	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
,	NULL
may	NULL
improve	NULL
the	NULL
survival	NULL
of	NULL
the	NULL
transduced	NULL
cells	NULL
and	NULL
prolong	NULL
the	NULL
clinical	NULL
benefit	NULL
that	NULL
is	NULL
seen	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Joseph	NULL
Sodroski	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
helpful	NULL
comments	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grants	NULL
P30	NULL
AI28691	NULL
(	NULL
Center	NULL
for	NULL
AIDS	NULL
Research	NULL
)	NULL
,	NULL
P30	NULL
CAO06516	NULL
(	NULL
Cancer	NULL
Center	NULL
grant	NULL
)	NULL
,	NULL
AI28785	NULL
,	NULL
AI33802	NULL
,	NULL
and	NULL
AI31783	NULL
and	NULL
the	NULL
Claudia	NULL
Adams	NULL
Barr	NULL
Innovative	NULL
Basic	NULL
Science	NULL
Program	NULL
.	NULL

This	NULL
work	NULL
was	NULL
also	NULL
made	NULL
possible	NULL
by	NULL
gifts	NULL
from	NULL
the	NULL
G.	NULL
Harold	NULL
and	NULL
Leila	NULL
Y.	NULL
Mathers	NULL
Charitable	NULL
Foundation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alcami	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Lera	NULL
,	NULL
L.	NULL
Folgueira	NULL
,	NULL
M.-A	NULL
.	NULL

Pedraza	NULL
,	NULL
J.-M.	NULL
Jacque	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
A.	NULL
R.	NULL
Noriega	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
R.	NULL
Gaynor	NULL
,	NULL
J.-L.	NULL
Virelizier	NULL
,	NULL
and	NULL
F.	NULL
A.	NULL
Seisdedos	NULL
.	NULL

1995	NULL
.	NULL

Absolute	NULL
dependence	NULL
on	NULL
NF-kB	NULL
responsive	NULL
elements	NULL
for	NULL
initiation	NULL
and	NULL
Tat-mediated	NULL
amplification	NULL
of	NULL
HIV	NULL
transcription	NULL
in	NULL
blood	NULL
CD4	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:1552-1560	NULL
.	NULL

2	NULL
.	NULL

Baltimore	NULL
,	NULL
D.	NULL
1988	NULL
.	NULL

Intracellular	NULL
immunization	NULL
.	NULL

Nature	NULL
335:395-396	NULL
.	NULL

3	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1989	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
is	NULL
sequence	NULL
specific	NULL
for	NULL
both	NULL
the	NULL
single-stranded	NULL
bulge	NULL
and	NULL
loop	NULL
of	NULL
the	NULL
transacting	NULL
responsive	NULL
hairpin	NULL
:	NULL
a	NULL
quantitative	NULL
analysis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:5501-5504	NULL
.	NULL

4	NULL
.	NULL

Biswas	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
C.	NULL
M.	NULL
Ahlers	NULL
,	NULL
B.	NULL
J.	NULL
Dezube	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
.	NULL

1993	NULL
.	NULL

Cooperative	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
and	NULL
Tat-induced	NULL
superactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:11044-11048	NULL
.	NULL

5	NULL
.	NULL

Biswas	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
B.	NULL
J.	NULL
Dezube	NULL
,	NULL
C.	NULL
M.	NULL
Ablers	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
.	NULL

1993	NULL
.	NULL

Pentoxifylline	NULL
inhibits	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
by	NULL
blocking	NULL
NF-	NULL
«	NULL
B	NULL
ac-tion	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

6:778-786	NULL
.	NULL

6	NULL
.	NULL

Biswas	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
C.	NULL
M.	NULL
Ahlers	NULL
,	NULL
B.	NULL
J.	NULL
Dezube	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
.	NULL

1994	NULL
.	NULL

Pentoxifylline	NULL
and	NULL
other	NULL
protein	NULL
kinase	NULL
C	NULL
inhibitors	NULL
down	NULL
regulate	NULL
HIV-LTR	NULL
NF-kB	NULL
induced	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Med	NULL
.	NULL

1:31-43	NULL
.	NULL

7	NULL
.	NULL

Biswas	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
T.	NULL
R.	NULL
Salas	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
C.	NULL
M.	NULL
Ablers	NULL
,	NULL
B.	NULL
J.	NULL
Dezube	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
Tat-induced	NULL
auto-up-regulatory	NULL
loop	NULL
for	NULL
superactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:7437-7444	NULL
.	NULL

8	NULL
.	NULL

Bunnell	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
L.	NULL
M.	NULL
Muul	NULL
,	NULL
R.	NULL
E.	NULL
Donahue	NULL
,	NULL
R.	NULL
M.	NULL
Blaese	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Morgan	NULL
.	NULL

1995	NULL
.	NULL

High-efficiency	NULL
retroviral-mediated	NULL
gene	NULL
transfer	NULL
into	NULL
human	NULL
and	NULL
nonhuman	NULL
primate	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:7739-7743	NULL
.	NULL

9	NULL
.	NULL

Buonaguro	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Barillari	NULL
,	NULL
H.-K.	NULL
Chang	NULL
,	NULL
C.	NULL
Bohan	NULL
,	NULL
V.	NULL
Kao	NULL
,	NULL
R.	NULL
Morgan	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
B.	NULL
Ensoli	NULL
.	NULL

1992	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:7159-7167	NULL
.	NULL

10	NULL
.	NULL

Buonaguro	NULL
,	NULL
L.	NULL
,	NULL
F.	NULL
M.	NULL
Buonaguro	NULL
,	NULL
G.	NULL
Giraldo	NULL
,	NULL
and	NULL
B.	NULL
Ensoli	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
transactivates	NULL
tumor	NULL
necrosis	NULL
factor	NULL
beta	NULL
gene	NULL
expression	NULL
through	NULL
a	NULL
TAR-like	NULL
structure	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2677-2682	NULL
.	NULL

11	NULL
.	NULL

Chen	NULL
,	NULL
J.	NULL
,	NULL
Q.	NULL
Yang	NULL
,	NULL
A.-G.	NULL
Yang	NULL
,	NULL
W.	NULL
A.	NULL
Marasco	NULL
,	NULL
and	NULL
S.-Y	NULL
.	NULL

Chen	NULL
.	NULL

1996	NULL
.	NULL

Intra-and	NULL
extra-cellular	NULL
immunization	NULL
against	NULL
HIV-1	NULL
infection	NULL
with	NULL
lymphocytes	NULL
transduced	NULL
with	NULL
an	NULL
AAV	NULL
vector	NULL
expressing	NULL
a	NULL
human	NULL
anti-gp120	NULL
antibody	NULL
gene	NULL
.	NULL

Human	NULL
Gene	NULL
Ther	NULL
.	NULL

7:1515-1525	NULL
.	NULL

12	NULL
.	NULL

Chen	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Y.	NULL
Khouri	NULL
,	NULL
J.	NULL
Bagley	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Marasco	NULL
.	NULL

1994	NULL
.	NULL

Combined	NULL
intra	NULL
and	NULL
extra-cellular	NULL
immunization	NULL
against	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
using	NULL
as	NULL
human	NULL
anti-gp120	NULL
antibody	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:5932-5936	NULL
.	NULL

13	NULL
.	NULL

Chen	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
J.	NULL
Bagley	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Marasco	NULL
.	NULL

1994	NULL
.	NULL

Intracellular	NULL
antibodies	NULL
as	NULL
a	NULL
new	NULL
class	NULL
of	NULL
therapeutic	NULL
molecules	NULL
for	NULL
gene	NULL
therapy	NULL
.	NULL

Hum	NULL
.	NULL

Gene	NULL
Ther	NULL
.	NULL

5:595-600	NULL
.	NULL

14	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Regulatory	NULL
pathways	NULL
governing	NULL
HIV-1	NULL
replication	NULL
.	NULL

Cell	NULL
58:423-426	NULL
.	NULL

15	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1992	NULL
.	NULL

Mechanism	NULL
of	NULL
action	NULL
of	NULL
regulatory	NULL
proteins	NULL
encoded	NULL
by	NULL
complex	NULL
retroviruses	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

56:375-394	NULL
.	NULL

16	NULL
.	NULL

Dezube	NULL
,	NULL
B.	NULL
J	NULL
.	NULL

1994	NULL
.	NULL

Pentoxifylline	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
infection	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Clin	NULL
.	NULL

Infect	NULL
.	NULL

Dis	NULL
.	NULL

18:285-287	NULL
.	NULL

17	NULL
.	NULL

Dezube	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
M.	NULL
M.	NULL
Lederman	NULL
,	NULL
J.	NULL
G.	NULL
Spritzler	NULL
,	NULL
B.	NULL
Chapman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Korvick	NULL
,	NULL
C.	NULL
Flexner	NULL
,	NULL
S.	NULL
Dando	NULL
,	NULL
M.	NULL
R.	NULL
Mattiacci	NULL
,	NULL
C.	NULL
M.	NULL
Ahlers	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

High	NULL
dose	NULL
pentoxifylline	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
:	NULL
inhibition	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
production	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

171:1628-1632	NULL
.	NULL

18	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

19	NULL
.	NULL

Dingwall	NULL
,	NULL
C.	NULL
,	NULL
I.	NULL
Ernberg	NULL
,	NULL
M.	NULL
J.	NULL
Gait	NULL
,	NULL
S.	NULL
M.	NULL
Green	NULL
,	NULL
S.	NULL
Heaphy	NULL
,	NULL
J.	NULL
Karn	NULL
,	NULL
A.	NULL
D.	NULL
Lowe	NULL
,	NULL
M.	NULL
Singh	NULL
,	NULL
M.	NULL
A.	NULL
Skinner	NULL
,	NULL
and	NULL
R.	NULL
Valero	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
Tat	NULL
protein	NULL
binds	NULL
trans-activation	NULL
responsive	NULL
region	NULL
(	NULL
TAR	NULL
)	NULL
ANTI-HIV-1	NULL
PHARMACOLOGIC-GENETIC	NULL
STRATEGY	NULL
-	NULL
6493	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

RNA	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:6925-6929	NULL
.	NULL

Duan	NULL
,	NULL
L.	NULL
,	NULL
O.	NULL
Bagasra	NULL
,	NULL
M.	NULL
A.	NULL
Laughlin	NULL
,	NULL
J.	NULL
W.	NULL
Oakes	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Pomerantz	NULL
.	NULL

1994	NULL
.	NULL

Potent	NULL
inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
by	NULL
an	NULL
intracellular	NULL
anti-Rev	NULL
single	NULL
chain	NULL
antibody	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:5075-5079	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
A.	NULL
M.	NULL
Macher	NULL
,	NULL
D.	NULL
L.	NULL
Longo	NULL
,	NULL
H.	NULL
C.	NULL
Lane	NULL
,	NULL
A.	NULL
H.	NULL
Rook	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
and	NULL
E.	NULL
P.	NULL
Gelmann	NULL
.	NULL

1994	NULL
.	NULL

Acquired	NULL
immunodeficiency	NULL
syndrome	NULL
:	NULL
epidemi-ologic	NULL
,	NULL
clinical	NULL
,	NULL
immunologic	NULL
and	NULL
therapeutic	NULL
considerations	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

100:92-99	NULL
.	NULL

Fazely	NULL
,	NULL
F.	NULL
,	NULL
B.	NULL
J.	NULL
Dezube	NULL
,	NULL
J.	NULL
Allen-Ryan	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Ruprecht	NULL
.	NULL

1991	NULL
.	NULL

Pentoxifylline	NULL
(	NULL
Trental	NULL
)	NULL
decreases	NULL
the	NULL
replication	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
and	NULL
in	NULL
cultured	NULL
T-cells	NULL
.	NULL

Blood	NULL
77:1653-1656	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
G.	NULL
M.	NULL
Shearer	NULL
,	NULL
M.	NULL
Kaplan	NULL
,	NULL
B.	NULL
F.	NULL
Hayes	NULL
,	NULL
T.	NULL
J.	NULL
Palker	NULL
,	NULL
R.	NULL
Redfield	NULL
,	NULL
J.	NULL
Oleske	NULL
,	NULL
B.	NULL
Safai	NULL
,	NULL
G.	NULL
White	NULL
,	NULL
and	NULL
P.	NULL
Foster	NULL
.	NULL

1984	NULL
.	NULL

Frequent	NULL
detection	NULL
and	NULL
isolation	NULL
of	NULL
cytopathic	NULL
retroviruses	NULL
(	NULL
HTLV-IIT	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
at	NULL
risk	NULL
for	NULL
AIDS	NULL
.	NULL

Science	NULL
224:500-503	NULL
.	NULL

Gatignol	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Buckler-White	NULL
,	NULL
B.	NULL
Berkhout	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1991	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
human	NULL
TAR	NULL
RNA-binding	NULL
protein	NULL
that	NULL
activates	NULL
the	NULL
HIV-1	NULL
TAR	NULL
.	NULL

Science	NULL
251:1597-1600.	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
E.	NULL
Soultanakis	NULL
,	NULL
M.	NULL
Kuwabara	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Sigman	NULL
.	NULL

1989	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
protein	NULL
to	NULL
RNA	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transactivating	NULL
region	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:4858-4862	NULL
.	NULL

Gilboa	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
C.	NULL
Smith	NULL
.	NULL

1994	NULL
.	NULL

Gene	NULL
therapy	NULL
for	NULL
infectious	NULL
diseases	NULL
:	NULL
the	NULL
AIDS	NULL
model	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

10:139-144	NULL
.	NULL

Greenblatt	NULL
,	NULL
J.	NULL
,	NULL
J.	NULL
R.	NULL
Nodwell	NULL
,	NULL
and	NULL
S.	NULL
W.	NULL
Mason	NULL
.	NULL

1993	NULL
.	NULL

Transcriptional	NULL
anti-termination	NULL
.	NULL

Nature	NULL
364:401-406	NULL
.	NULL

Haseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

1991	NULL
.	NULL

Molecular	NULL
biology	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2349-2360	NULL
.	NULL

Helland	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
J.	NULL
L	NULL
Welles	NULL
,	NULL
A.	NULL
Caputo	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1991	NULL
.	NULL

Transcellular	NULL
transactivation	NULL
by	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4547-4549	NULL
.	NULL

Hsu	NULL
,	NULL
M.-C.	NULL
,	NULL
A.	NULL
D.	NULL
Schutt	NULL
,	NULL
M.	NULL
Holly	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
acute	NULL
and	NULL
chronic	NULL
infectious	NULL
in-vitro	NULL
by	NULL
a	NULL
tat	NULL
antagonist	NULL
.	NULL

Science	NULL
254:1799-1802	NULL
.	NULL

Kamine	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1992	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
by	NULL
the	NULL
viral	NULL
Tat	NULL
protein	NULL
and	NULL
cellular	NULL
transcription	NULL
factor	NULL
SPL	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3926-3932	NULL
.	NULL

Kashanchi	NULL
,	NULL
F.	NULL
,	NULL
G.	NULL
Piras	NULL
,	NULL
M.	NULL
F.	NULL
Rodonovich	NULL
,	NULL
J.	NULL
F.	NULL
Duvall	NULL
,	NULL
A.	NULL
Fattaey	NULL
,	NULL
C.-M.	NULL
Chiang	NULL
,	NULL
R.	NULL
G.	NULL
Roder	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Brady	NULL
.	NULL

1994	NULL
.	NULL

Direct	NULL
interaction	NULL
of	NULL
human	NULL
TFIID	NULL
with	NULL
the	NULL
HIV-1	NULL
transactivator	NULL
Tat	NULL
.	NULL

Nature	NULL
367:295-299	NULL
.	NULL

Laspia	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
A.	NULL
P.	NULL
Rice	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1989	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
increases	NULL
transcriptional	NULL
initiation	NULL
and	NULL
stabilizes	NULL
elongation	NULL
.	NULL

Cell	NULL
59:282-292	NULL
.	NULL

Levin	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
M.	NULL
Mhashilkar	NULL
,	NULL
T.	NULL
Dorfman	NULL
,	NULL
A.	NULL
Bukovsky	NULL
,	NULL
C.	NULL
Zani	NULL
,	NULL
J.	NULL
Bagley	NULL
,	NULL
J.	NULL
Hinkula	NULL
,	NULL
M.	NULL
Niedrig	NULL
,	NULL
J.	NULL
Albert	NULL
,	NULL
B.	NULL
Wahren	NULL
,	NULL
H.	NULL
G.	NULL
Gittlinger	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Marasco	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
early	NULL
and	NULL
late	NULL
events	NULL
of	NULL
the	NULL
HIV-1	NULL
replication	NULL
cycle	NULL
by	NULL
cytoplasmic	NULL
Fab	NULL
intrabodies	NULL
against	NULL
the	NULL
matrix	NULL
protein	NULL
,	NULL
p17	NULL
.	NULL

Mol	NULL
.	NULL

Med	NULL
.	NULL

3:96-110	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
D.	NULL
Perkins	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Specific	NULL
NF-kB	NULL
subunits	NULL
act	NULL
in	NULL
concert	NULL
with	NULL
Tat	NULL
to	NULL
stimulate	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transcription	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3883-3887	NULL
.	NULL

Maciejewski	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
F.	NULL
F.	NULL
Weichold	NULL
,	NULL
N.	NULL
S.	NULL
Young	NULL
,	NULL
A.	NULL
Cara	NULL
,	NULL
D.	NULL
Zella	NULL
,	NULL
M.	NULL
S.	NULL
Reitz	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1995	NULL
.	NULL

Intracellular	NULL
expression	NULL
of	NULL
antibody	NULL
fragments	NULL
directed	NULL
against	NULL
HIV	NULL
reverse	NULL
transcriptase	NULL
prevents	NULL
HIV	NULL
infection	NULL
in	NULL
vitro	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

1:667-673	NULL
.	NULL

Madore	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Cullen	NULL
.	NULL

1993	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
the	NULL
cofactor	NULL
requirement	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
tat	NULL
function	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:3703-3711	NULL
.	NULL

Malim	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
J.	NULL
Hauber	NULL
,	NULL
R.	NULL
Fenrick	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Cullen	NULL
.	NULL

1988	NULL
.	NULL

Immunodeficiency	NULL
virus	NULL
rev	NULL
transactivator	NULL
modulates	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
regulatory	NULL
genes	NULL
.	NULL

Nature	NULL
335:181-183	NULL
.	NULL

Marasco	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
and	NULL
S.-Y	NULL
.	NULL

Chen	NULL
.	NULL

1993	NULL
.	NULL

Design	NULL
,	NULL
intracellular	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
a	NULL
human	NULL
anti-human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
gp120	NULL
single-chain	NULL
antibody	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7889-7893	NULL
.	NULL

Marasco	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

1995	NULL
.	NULL

Intracellular	NULL
antibodies	NULL
``	NULL
intrabodies	NULL
``	NULL
as	NULL
research	NULL
reagents	NULL
and	NULL
therapeutic	NULL
molecules	NULL
for	NULL
gene	NULL
therapy	NULL
.	NULL

Immunotechnology	NULL
1:1-19	NULL
.	NULL

Marasco	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

1997	NULL
.	NULL

Intrabodics	NULL
:	NULL
turning	NULL
the	NULL
humoral	NULL
immune	NULL
system	NULL
outside	NULL
in	NULL
for	NULL
intracellular	NULL
immunization	NULL
.	NULL

Gene	NULL
Ther	NULL
.	NULL

411-15	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Garcia-Blanco	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
HeLa	NULL
nuclear	NULL
protein	NULL
that	NULL
specifically	NULL
binds	NULL
to	NULL
transactivation	NULL
response	NULL
(	NULL
TAR	NULL
)	NULL
element	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:3624-3638	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1991	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
promotes	NULL
formation	NULL
of	NULL
more	NULL
processive	NULL
elongation	NULL
complexes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:4189-4196	NULL
.	NULL

Mhashilkar	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
Bagley	NULL
,	NULL
S.-Y	NULL
.	NULL

Chen	NULL
,	NULL
A.	NULL
M.	NULL
Szilvay	NULL
,	NULL
D.	NULL
G.	NULL
Helland	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Marasco	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
Tat	NULL
mediated	NULL
LTR	NULL
transactivation	NULL
and	NULL
HIV-1	NULL
infection	NULL
by	NULL
anti-Tat	NULL
single-chain	NULL
antibodies	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:1542-1551	NULL
.	NULL

Mhashilkar	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
S.	NULL
Agarwal	NULL
,	NULL
S.	NULL
Levin	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Marasco	NULL
.	NULL

1996	NULL
.	NULL

Genetic	NULL
6494	NULL
46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

MHASHILKAR	NULL
ET	NULL
AL	NULL
.	NULL

based	NULL
strategies	NULL
for	NULL
control	NULL
of	NULL
HIV-1	NULL
:	NULL
Tat	NULL
and	NULL
Rev	NULL
as	NULL
potential	NULL
targets	NULL
.	NULL

Drug	NULL
News	NULL
Perspect	NULL
.	NULL

9	NULL
(	NULL
4	NULL
)	NULL
:220-227	NULL
.	NULL

Miller	NULL
,	NULL
A.	NULL
D.	NULL
1991	NULL
.	NULL

Retroviral	NULL
vectors	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

158	NULL
:	NULL
1-23	NULL
.	NULL

Morgan	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
K.	NULL
Cornetta	NULL
,	NULL
and	NULL
W.	NULL
F.	NULL
Anderson	NULL
.	NULL

1990	NULL
.	NULL

Applications	NULL
of	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
in	NULL
retroviral-mediated	NULL
gene	NULL
transfer	NULL
and	NULL
the	NULL
analysis	NULL
of	NULL
gene-marked	NULL
human	NULL
TIL	NULL
cells	NULL
.	NULL

Human	NULL
Gene	NULL
Ther	NULL
.	NULL

1:135-149	NULL
.	NULL

Ohana	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
A.	NULL
Moore	NULL
,	NULL
S.	NULL
R.	NULL
Ruben	NULL
,	NULL
C.	NULL
D.	NULL
Southgate	NULL
,	NULL
M.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
type	NULL
1	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
binding	NULL
protein	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
belonging	NULL
to	NULL
an	NULL
additional	NULL
family	NULL
of	NULL
evolutionary	NULL
conserved	NULL
genes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:138-142	NULL
.	NULL

482.O0tt	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Emiliani	NULL
,	NULL
C.	NULL
Van	NULL
Lint	NULL
,	NULL
G.	NULL
Herbein	NULL
,	NULL
J.	NULL
Lovett	NULL
,	NULL
N.	NULL
Chirmule	NULL
,	NULL
T.	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

McCloskey	NULL
,	NULL
S.	NULL
Pahwa	NULL
,	NULL
and	NULL
E.	NULL
Verdin	NULL
.	NULL

1997	NULL
.	NULL

Immune	NULL
hyperactivation	NULL
of	NULL
HIV-1-infected	NULL
T	NULL
cells	NULL
by	NULL
Tat	NULL
and	NULL
the	NULL
CD28	NULL
pathway	NULL
.	NULL

Science	NULL
275:1481-1485	NULL
.	NULL

Poznansky	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
R.	NULL
Foxall	NULL
,	NULL
U.	NULL
Ramstedt	NULL
,	NULL
R.	NULL
Coker	NULL
,	NULL
A.	NULL
Mhashilkar	NULL
,	NULL
W.	NULL
A.	NULL
Marasco	NULL
,	NULL
and	NULL
J.	NULL
Weber	NULL
.	NULL

Intracellular	NULL
antibodies	NULL
against	NULL
Tat	NULL
and	NULL
gp120	NULL
inhibit	NULL
the	NULL
replication	NULL
of	NULL
HIV-1	NULL
in	NULL
T-cells	NULL
from	NULL
HIV-infected	NULL
individuals	NULL
.	NULL

Human	NULL
Gene	NULL
Ther	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Qatsha	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
C.	NULL
Rudolph	NULL
,	NULL
D.	NULL
Marme	NULL
,	NULL
C.	NULL
Schachtele	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
May	NULL
.	NULL

1993	NULL
.	NULL

Go	NULL
6976	NULL
selective	NULL
inhibitor	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
is	NULL
a	NULL
potent	NULL
antagonist	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
induction	NULL
from	NULL
latent/low	NULL
level	NULL
producing	NULL
reservoir	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:4674-4678	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
U.	NULL
Delling	NULL
,	NULL
C.-H.	NULL
Chen	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

bulge	NULL
structure	NULL
in	NULL
HIV-1	NULL
TAR	NULL
RNA	NULL
is	NULL
required	NULL
for	NULL
Tat-binding	NULL
and	NULL
Tat-mediated	NULL
transactivation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1365-1373	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
N.	NULL
T.	NULL
Parkin	NULL
,	NULL
C.	NULL
Rosen	NULL
,	NULL
J.	NULL
Itovitch	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
.	NULL

1990	NULL
.	NULL

Structural	NULL
requirements	NULL
for	NULL
frans-activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat-directed	NULL
gene	NULL
expression	NULL
by	NULL
Tat	NULL
:	NULL
importance	NULL
of	NULL
base	NULL
pairing	NULL
,	NULL
loop	NULL
sequences	NULL
,	NULL
and	NULL
bulges	NULL
in	NULL
the	NULL
Tat-responsive	NULL
sequences	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1402-1406	NULL
.	NULL

Sastry	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
R.	NULL
H.	NULL
R.	NULL
Reddy	NULL
,	NULL
R.	NULL
Pandita	NULL
,	NULL
K.	NULL
Totpal	NULL
,	NULL
and	NULL
B	NULL
.	NULL

B.	NULL
Aggarwal	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
Tat	NULL
gene	NULL
induces	NULL
tumor	NULL
necrosis	NULL
factor	NULL
B	NULL
(	NULL
lymphotoxin	NULL
)	NULL
in	NULL
human	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:20091-20093	NULL
.	NULL

Shaheen	NULL
,	NULL
F.	NULL
,	NULL
L.	NULL
Duan	NULL
,	NULL
M.	NULL
Zhu	NULL
,	NULL
O.	NULL
Bagasra	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Pomerantz	NULL
.	NULL

1996	NULL
.	NULL

Targeting	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
reverse	NULL
transcriptase	NULL
by	NULL
intracellular	NULL
expression	NULL
of	NULL
single-chain	NULL
variable	NULL
fragments	NULL
to	NULL
inhibit	NULL
carly	NULL
stages	NULL
of	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:3392-3400	NULL
.	NULL

Sheline	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
M.	NULL
H.	NULL
Milocco	NULL
,	NULL
and	NULL
K.	NULL
H.	NULL
Jones	NULL
.	NULL

1991	NULL
.	NULL

Two	NULL
distinct	NULL
nuclear	NULL
transcriptional	NULL
factors	NULL
recognize	NULL
loop	NULL
and	NULL
bulge	NULL
residues	NULL
of	NULL
the	NULL
HIV-1	NULL
TAR	NULL
RNA	NULL
hair	NULL
pin	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2508-2520	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Irie	NULL
,	NULL
J.	NULL
Ninimlya-Tsuji	NULL
,	NULL
M.	NULL
Goebit	NULL
,	NULL
T.	NULL
Taniguchi	NULL
,	NULL
and	NULL
K.	NULL
Matsumoto	NULL
.	NULL

1992	NULL
.	NULL

New	NULL
human	NULL
gene	NULL
encoding	NULL
a	NULL
positive	NULL
modulator	NULL
of	NULL
HIV	NULL
Tat	NULL
mediated	NULL
transactivation	NULL
.	NULL

Nature	NULL
357:700-702	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Rosen	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
S.	NULL
Arya	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

Trans-acting	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
type-II	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Science	NULL
227:171-173	NULL
.	NULL

Westendorp	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
M.	NULL
Li-Weber	NULL
,	NULL
R.	NULL
W.	NULL
Frank	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
upregulates	NULL
interleukin-2	NULL
secretion	NULL
in	NULL
activated	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:4177-4185	NULL
.	NULL

